Central Serous Chorioretinopathy

Complex MONDO:0018616 Pathograph 14 Show in embeddings browser Retinal Disorder

Central serous chorioretinopathy (CSCR) is a pachychoroid spectrum disorder characterized by focal serous detachment of the neural retina and/or retinal pigment epithelium (RPE) in the posterior pole, caused by choroidal hyperpermeability and RPE barrier dysfunction. First described by Albrecht von Graefe in 1866, CSCR predominantly affects middle-aged adults (peak incidence 30–50 years) with a strong male predominance (72–87.5% male). Acute CSCR is typically self-limiting, with spontaneous subretinal fluid (SRF) resolution in approximately 90–95% of cases within 2–3 months; chronic CSCR (persistent SRF beyond 3–4 months) causes progressive RPE decompensation, photoreceptor damage, and permanent vision loss in a subset. Disease etiology is complex and multifactorial: glucocorticoid and mineralocorticoid receptor overstimulation drives choroidal hyperpermeability, while GWAS loci including CFH, PTPRB, TNFRSF10A, GATA5, and NR3C2 confer polygenic susceptibility. Half-dose verteporfin photodynamic therapy is the established treatment of choice for chronic CSCR.

Ask OpenScientist

Ask a research question about Central Serous Chorioretinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
10
Phenotypes
1
Gaps
14
Pathograph
6
Medical Actions
2
Subtypes
7
References
2
Deep Research
◆

Subtypes

2
Acute CSCR
Self-limiting form lasting less than 3–4 months. Subretinal fluid resolves spontaneously with recovery of visual acuity in approximately 90–95% of cases. Most common form, predominantly affecting young to middle-aged males under psychological or corticosteroid-related stress. Recurrence rates of 15–50% are observed across series.
Show evidence (1 reference)
DOI:10.1186/s40662-023-00349-y SUPPORT Human Clinical
"CSCR is the first ever described pachychoroid disease. Most recently, hypothetical venous overload choroidopathy is also proposed due to its distinguished morphological and pathological characteristics, including choroidal thickening, choriocapillaris hyperpermeability, remodelling, and..."
Comprehensive 2023 review documents CSCR as a pachychoroid spectrum disorder, defining its distinctive choroidal pathology relevant to both acute and chronic subtypes.
Chronic CSCR
Persistent form lasting more than 3–4 months, defined by continuing subretinal fluid with progressive RPE decompensation. Associated with diffuse RPE atrophy, photoreceptor outer segment disruption, and risk of choroidal neovascularization (CNV) in 2–15.6% of cases. Approximately 12.8% develop legal blindness after mean 11.3-year follow-up without treatment. Intervention with half-dose PDT is indicated when SRF persists beyond 3–4 months.
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability. A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with..."
International expert consensus review distinguishes chronic CSC as requiring active treatment (PDT) and identifies CNV as a known serious complication requiring anti-VEGF.
?

Discussions and Knowledge Gaps

1
Do available animal models (aldosterone-induced rat, choroidal congestion mouse, adrenaline-induced rabbit) faithfully reproduce the human CSCR pachychoroid phenotype—with its distinctive dilated Haller's layer vessels, choriocapillaris attenuation, and RPE focal breakdown driven by chronic venous congestion—or does the absence of a pachychoroid anatomical substrate in rodents and lagomorphs mean that these models address only individual upstream triggers (hormonal, vascular congestion) rather than the full human disease spectrum?
HUMAN MODEL MISMATCH OPEN gap_cscr_pachychoroid_animal_model_mismatch
Attached to
pathophysiology#Choroidal Hyperpermeability and Pachychoroid Dysfunction pathophysiology#Mineralocorticoid and Glucocorticoid Receptor Overstimulation
Current animal models recapitulate specific upstream mechanisms: aldosterone treatment in rats produces subretinal fluid and RPE changes consistent with mineralocorticoid receptor overstimulation, and choroidal congestion mouse models address some aspects of vascular hyperpermeability. However, no animal species possesses a pachychoroid anatomy (thickened choroid with enlarged Haller's layer vessels and attenuated choriocapillaris) homologous to the human lesion. The genetic risk architecture—particularly CFH pathway and PTPRB variants—is not modeled by any existing system. This mismatch limits translational inference: pharmacological effects shown in rodent models (e.g., melatonin preventing aldosterone-induced SRF in rats) may not reflect efficacy against the full human pachychoroid disease. Validating the PTPRB-VE-PTP and CFH mechanisms requires species with relevant choroidal anatomy or humanized vascular endothelial systems.
Proposed experiments
Non-human primate model with pachychoroid-like anatomy for CSCR validation
exp_cscr_primate_pachychoroid
Identify or induce a pachychoroid phenotype in macaques or marmosets (which have thicker choroids than rodents) via aldosterone + corticosteroid exposure to test whether the mineralocorticoid receptor and PTPRB pathways operate in a choroidal vascular bed more analogous to the human CSCR substrate.
⚙

Pathophysiology

5
Mineralocorticoid and Glucocorticoid Receptor Overstimulation
Elevated glucocorticoids and mineralocorticoids—from exogenous corticosteroid use, endogenous hypercortisolism, or stress-driven neuroendocrine activation— overstimulate mineralocorticoid receptors (MR; encoded by NR3C2) in choroidal endothelial cells. This upregulates vascular permeability factors, disrupts endothelial tight junctions, and promotes choroidal congestion. The NR3C2 gene is a GWAS susceptibility locus for CSCR, linking genetic predisposition to the glucocorticoid/mineralocorticoid axis. Corticosteroid use is the strongest and most consistently documented modifiable environmental risk factor for CSCR, producing more severe disease with higher recurrence and bilateral involvement.
glucocorticoid receptor signaling pathway GO:0042921 ↑ INCREASED
Downstream
Choroidal Hyperpermeability and Pachychoroid Dysfunction MR overstimulation in choroidal endothelial cells upregulates vascular permeability factors and disrupts tight junctions, causing choroidal congestion and hyperpermeability.
Show evidence (2 references)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"Recent evidence describing the pathogenesis of and risk factors for CSC focuses on possible dysfunction of the choroid and retinal pigment epithelium, and the role of corticosteroids. It is suggested that CSC lies within the spectrum of pachychoroid disorders that share the characteristic of..."
2025 international expert review directly implicates corticosteroids and choroid-RPE dysfunction in CSCR pathogenesis, consistent with the mineralocorticoid receptor mechanism.
DOI:10.1186/s40662-023-00349-y SUPPORT Human Clinical
"The use of oral eplerenone for routine clinical care remains controversial, and long-term randomized clinical trials are warranted to investigate its efficacy in acute and chronic CSCR."
Review discusses mineralocorticoid receptor antagonists (eplerenone) as the direct pharmacological rationale for targeting MR overstimulation in CSCR, establishing the pathway's clinical relevance.
Choroidal Hyperpermeability and Pachychoroid Dysfunction
The primary anatomical and vascular event in CSCR is choroidal hyperpermeability with thickening and dilation of the choroid, especially in Haller's outer vascular layer (pachyvessels). Choriocapillaris hyperpermeability and attenuation of the inner layers (Sattler's layer) follow. CSCR is classified as the first described pachychoroid spectrum disease, a group characterized by dilated outer choroidal vessels driving pressure-mediated choriocapillaris dysfunction. Intervortex venous anastomoses and choroidal venous congestion may reflect underlying vascular endothelial phosphatase (VE-PTP; PTPRB) dysfunction and abnormal choroidal venous drainage, supporting the recently proposed "venous overload choroidopathy" hypothesis.
choroidal endothelial cell CL:0000115
positive regulation of vascular permeability GO:0043117 ↑ INCREASED blood vessel remodeling GO:0001974 ⚠ ABNORMAL
choroid UBERON:0001776
Downstream
Retinal Pigment Epithelium Dysfunction Increased hydrostatic pressure from congested choroidal vessels overwhelms RPE pump capacity and tight junction integrity, causing focal RPE breakdown and sub-RPE fluid accumulation.
Show evidence (2 references)
DOI:10.1186/s40662-023-00349-y SUPPORT Human Clinical
"CSCR is the first ever described pachychoroid disease. Most recently, hypothetical venous overload choroidopathy is also proposed due to its distinguished morphological and pathological characteristics, including choroidal thickening, choriocapillaris hyperpermeability, remodelling, and..."
Landmark 2023 review establishes choroidal hyperpermeability and pachychoroid anatomy as the defining pathological feature of CSCR and introduces the venous overload choroidopathy model.
DOI:10.1038/s41467-025-58686-6 SUPPORT Human Clinical
"The rs113791087 missense variant in PTPRB encoding vascular endothelial protein tyrosine phosphatase (VE-PTP) confers OR = 3.06 (P = 7.4 x 10^-15) in a meta-analysis of 2,452 CSC patients and 865,767 controls across four studies, and abnormal choroidal veins in CSC patients share morphological..."
2025 Nature Communications study identifies VE-PTP (PTPRB) as the strongest single-variant risk factor for CSCR, directly linking vascular endothelial phosphatase dysfunction to choroidal venous pathology.
Complement Factor H Pathway Dysregulation
Genetic variation at the CFH locus (1q31.3) is among the most consistently replicated susceptibility signals for CSCR across multiple GWAS. Complement factor H (CFH) and its related proteins (CFHR1-5) regulate the alternative complement pathway through competition for C3b binding. GWAS meta-analyses identify 26 CFH- or CFHR-related biological pathways with genome-wide significant associations with CSCR susceptibility. Protein quantitative trait loci analyses support protein-level contribution of the CFH pathway to CSCR pathogenesis. The mechanism likely involves local complement dysregulation in the choroidal-RPE interface, driving tissue damage and chronic vascular inflammation, in parallel with the mineralocorticoid pathway.
complement activation GO:0006956 ↑ INCREASED
Downstream
Retinal Pigment Epithelium Dysfunction Complement dysregulation at the choroid-RPE interface promotes local inflammation and tissue injury, compounding the hydrostatic stress from choroidal hyperpermeability to drive RPE decompensation.
Show evidence (2 references)
DOI:10.1038/s41598-025-92210-6 SUPPORT Human Clinical
"A meta-analysis of three GWAS comprising 8,811 Asians and Caucasians with replication in 4,338 additional Asians identified seven genome-wide significant loci including CFH, TNFRSF10A, GATA5, CDH5, and VIPR2, with 26 CFH- or CFHR-related pathways showing significant associations indicating the..."
2025 multi-ethnic GWAS meta-analysis identifies CFH-pathway dysregulation as a central genetic mechanism in CSCR, supported by protein QTL and pathway enrichment analyses.
DOI:10.1016/j.xops.2025.101043 SUPPORT Human Clinical
"The CFH rs1329428 variant showed significant association with chronic CSCR with macular neovascularization, and 26 CFH- or CFHR-related pathways were significantly associated in GWAS analyses."
2026 multi-disease genetic study confirms the CFH-CFHR5 locus as a shared risk factor across pachychoroid spectrum disorders, with particular relevance to chronic CSCR with neovascular complications.
Retinal Pigment Epithelium Dysfunction
Hydrostatic and complement-mediated stress from the congested pachychoroid leads to focal RPE breakdown. RPE cells lose tight junction integrity and ion transport function, allowing fluid to leak through focal RPE defects into the subretinal space, visible as fluorescein angiography leakage points. In acute CSCR, single focal leaks predominate; in chronic CSCR, diffuse RPE atrophy and decompensation develop. Reduced serum lipocalin 2 (LCN2/NGAL) in CSCR patients reflects susceptibility to excessive oxidative stress and innate immune dysregulation, compounding RPE barrier failure.
retinal pigment epithelial cell CL:0002586
monoatomic ion transport GO:0006811 ↓ DECREASED response to oxidative stress GO:0006979 ↑ INCREASED
Downstream
Subretinal Fluid Accumulation and Photoreceptor Injury Focal RPE breakdown allows transudation of fluid from the sub-RPE space into the subretinal compartment, creating the neurosensory retinal detachment that is the defining anatomical lesion of CSCR.
Show evidence (1 reference)
DOI:10.1038/s41598-020-77202-y SUPPORT Human Clinical
"In both acute and chronic CSCR, low serum LCN2 and NGAL/MMP-9, provide a biological link between the two CSCR forms, and potential susceptibility to oxidative stress and innate immune dysregulation in CSCR."
Case-control study in 147 CSCR patients demonstrates significantly reduced serum LCN2 across both CSCR subtypes, implicating oxidative stress susceptibility and innate immune dysregulation as contributors to RPE barrier failure.
Subretinal Fluid Accumulation and Photoreceptor Injury
Fluid accumulation beneath the neurosensory retina separates the photoreceptor layer from the RPE, disrupting outer segment renewal, nutritional exchange, and visual signal transduction. Photoreceptor outer segments elongate abnormally in response to subretinal fluid; the ellipsoidal zone (EZ) band disruption on OCT correlates directly with visual acuity loss. Prolonged detachment in chronic CSCR leads to progressive photoreceptor atrophy, ganglion cell loss, and permanent visual impairment. Choroidal neovascularization (CNV; type 1) develops in 2–15.6% of chronic CSCR eyes and further threatens visual prognosis. Legal blindness develops in approximately 12.8% of patients after mean 11.3-year follow-up.
photoreceptor cell CL:0000210
visual perception GO:0007601 ↓ DECREASED positive regulation of angiogenesis GO:0045766 ↑ INCREASED
macula lutea UBERON:0000053 retina UBERON:0000966
Show evidence (1 reference)
DOI:10.1186/s40662-023-00349-y SUPPORT Human Clinical
"Half-dose photodynamic therapy (PDT) remains the mainstay of clinical practice, with about 95% of patients with chronic CSCR improving to visual acuity (VA) of 20/30 or better."
Comprehensive review documents the visual prognosis of chronic CSCR with and without treatment, confirming subretinal fluid-driven photoreceptor injury as the primary determinant of visual outcomes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Central Serous Chorioretinopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Eye 5
Blurred Central Vision OBLIGATE Visual impairment HP:0000505
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet defines blurred vision as a cardinal symptom of CSCR, consistent with subretinal fluid-mediated photoreceptor displacement as the defining pathological feature.
Relative Central Scotoma VERY_FREQUENT Central scotoma HP:0000603
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet record explicitly lists relative central scotoma as a defining symptom, reflecting the focal macular subretinal fluid accumulation that characterizes CSCR.
Hypermetropic Shift VERY_FREQUENT Hypermetropia HP:0000540
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet record includes hypermetropization (hypermetropic shift) as a characteristic symptom of CSCR, reflecting the refractive effect of retinal elevation by subretinal fluid.
Photopsia OCCASIONAL Photopsia HP:0030786
Macular Atrophy OCCASIONAL Macular atrophy HP:0007401
Other 5
Metamorphopsia VERY_FREQUENT Metamorphopsia HP:0012508
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet record lists metamorphopsia as a defining symptom of CSCR, caused by photoreceptor displacement from subretinal fluid accumulation under the macula.
Reduced Contrast Sensitivity FREQUENT Reduced contrast sensitivity HP:0032036
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet record lists reduced contrast sensitivity as a defining feature of CSCR, consistent with photoreceptor outer segment dysfunction in the detached macula.
Choroidal Neovascularization OCCASIONAL Choroidal neovascularization HP:0011506
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with intravitreal anti-vascular endothelial growth factor agents."
2025 consensus review identifies CNV as a documented complication of chronic CSCR requiring anti-VEGF therapy, distinct from the choroidal hyperpermeability managed with PDT.
Dyschromatopsia OCCASIONAL Dyschromatopsia HP:0007641
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet explicitly lists moderate dyschromatopsia as a characteristic symptom of CSCR, consistent with cone photoreceptor dysfunction from subretinal fluid in the macula.
Micropsia OCCASIONAL Metamorphopsia HP:0012508
Show evidence (1 reference)
ORPHA:443079 SUPPORT Human Clinical
"Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
Orphanet explicitly lists micropsia as a symptom of CSCR, distinct from metamorphopsia, caused by photoreceptor displacement and spreading by the subretinal fluid dome.
💊

Medical Actions

6
Observation and Risk Factor Modification
Action: Supportive care Ontology label: supportive care MAXO:0000950
First-line approach for acute CSCR, as approximately 90–95% of cases spontaneously resolve within 2–3 months. Observation includes: discontinuation of corticosteroids when possible, management of psychosocial stress, treatment of obstructive sleep apnea, and close monitoring with OCT and visual acuity assessments at 4–6 week intervals. Intervention is considered if SRF persists beyond 3–4 months or if the patient has special visual demands. Recurrence rates remain 15–50% after resolution, higher without treatment.
Target Phenotypes: Visual impairment HP:0000505
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"We propose a step-wise chart for clinical decision-making in the management and treatment of CSC. New data on long-term visual outcomes and the pathogenesis of CSC in relation to the pachychoroid disease spectrum provide a better understanding to inform our management of this disease."
2025 international expert consensus proposes a step-wise management algorithm in which observation with risk factor modification is the initial strategy for uncomplicated acute CSCR.
Half-Dose Verteporfin Photodynamic Therapy
Action: Photodynamic therapy Ontology label: Photodynamic Therapy NCIT:C15300
Agent: verteporfin CHEBI:32293
Half-dose (3 mg/m² instead of 6 mg/m²) photodynamic therapy with verteporfin is the established treatment of choice for chronic CSCR. Verteporfin selectively accumulates in abnormal choroidal vessels; laser activation at 689 nm induces choriocapillaris vascular remodeling, reducing choroidal hyperpermeability and subretinal fluid accumulation. Half-dose protocol minimizes RPE damage compared to standard PDT. SRF resolution rates exceed 91% at 19 months; approximately 95% of treated patients achieve VA of 20/30 or better. PDT reduces recurrence to approximately 20% versus 53.8% with observation alone. The PLACE randomized trial demonstrated superiority of half-dose PDT over high-density subthreshold micropulse laser in chronic CSCR. Half-fluence PDT is an alternative reduced dosing strategy with comparable safety.
Mechanism Target:
INHIBITS Choroidal Hyperpermeability and Pachychoroid Dysfunction — Verteporfin PDT causes targeted choriocapillaris occlusion and remodeling of abnormal choroidal vessels, normalizing choroidal permeability and reducing subretinal fluid generation.
Target Phenotypes: Visual impairment HP:0000505
Show evidence (2 references)
DOI:10.1186/s40662-023-00349-y SUPPORT Human Clinical
"Half-dose photodynamic therapy (PDT) remains the mainstay of clinical practice, with about 95% of patients with chronic CSCR improving to visual acuity (VA) of 20/30 or better."
Comprehensive 2023 review establishes half-dose PDT as the mainstay treatment for chronic CSCR, with approximately 95% of patients achieving VA 20/30 or better.
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability."
2025 international expert consensus review recommends half-dose/half-fluence PDT as the treatment of choice for CSCR, targeting the underlying choroidal hyperpermeability.
Mineralocorticoid Receptor Antagonists
Action: Pharmacotherapy NCIT:C15986
Agent: eplerenone CHEBI:31547 spironolactone CHEBI:9241
Eplerenone and spironolactone, oral mineralocorticoid receptor antagonists, were investigated as pharmacological treatments targeting the MR/cortisol pathway implicated in CSCR pathogenesis. The VICI randomized controlled trial (eplerenone vs. placebo in chronic CSCR) failed to meet its primary endpoint of improving best-corrected visual acuity at 12 months. Despite mechanistic rationale and early observational evidence, eplerenone did not demonstrate significant benefit over placebo for visual acuity in this pivotal trial. Routine use for chronic CSCR remains controversial; these agents may be considered when PDT is unavailable or contraindicated, but are not a substitute for PDT. Long-term RCT data are warranted before routine clinical adoption.
Mechanism Target:
INHIBITS Mineralocorticoid and Glucocorticoid Receptor Overstimulation — MR antagonists block mineralocorticoid receptor signaling in choroidal endothelial cells, theoretically reducing vascular permeability; however, clinical benefit in BCVA was not demonstrated in the VICI RCT.
Show evidence (1 reference)
DOI:10.1186/s40662-023-00349-y REFUTE Human Clinical
"The use of oral eplerenone for routine clinical care remains controversial, and long-term randomized clinical trials are warranted to investigate its efficacy in acute and chronic CSCR."
2023 comprehensive review explicitly states eplerenone's routine use remains controversial after the VICI trial failed to demonstrate BCVA benefit, cautioning against its adoption as standard care.
Subthreshold Micropulse Laser
Action: Laser therapy Ontology label: Therapeutic Procedure NCIT:C49236
High-density subthreshold micropulse laser (577 nm HSML) delivers sub-lethal retinal laser energy to stimulate RPE function without causing visible burns. Complete SRF resolution rates range from 36–100% across studies. The PLACE randomized trial demonstrated that half-dose PDT was superior to high-density micropulse laser for chronic CSCR in SRF resolution rate and recurrence. Micropulse laser is a reasonable alternative when PDT is unavailable, contraindicated, or for extrafoveal leakage, but should not be preferred over PDT for chronic subfoveal CSCR.
Mechanism Target:
INHIBITS Retinal Pigment Epithelium Dysfunction — Subthreshold micropulse laser delivers sub-lethal thermal energy to the RPE, stimulating RPE cell function and reducing focal leakage without causing visible RPE burns or permanent tissue destruction.
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z PARTIAL Human Clinical
"Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability."
2025 expert review recommends PDT as the treatment of choice over micropulse laser, citing the PLACE trial results showing PDT superiority; micropulse is an acceptable but less effective alternative.
Focal Laser Photocoagulation
Action: Laser photocoagulation Ontology label: Infrared Photocoagulation Therapy NCIT:C62730
Focal laser photocoagulation of the leakage point(s) identified on fluorescein angiography can accelerate SRF resolution in acute CSCR with extrafoveal focal leakage. Not appropriate for subfoveal or juxtafoveal leaks due to risk of causing permanent scotoma. Historical 5-year data suggest fewer recurrences and better VA than observation in some studies. Less commonly used since PDT has demonstrated superior outcomes for chronic and subfoveal CSCR.
Mechanism Target:
INHIBITS Retinal Pigment Epithelium Dysfunction — Focal laser photocoagulation creates a controlled thermal burn at the focal RPE leakage point identified on fluorescein angiography, sealing the defect and halting subretinal fluid transudation. Restricted to extrafoveal leaks to avoid central scotoma.
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z PARTIAL Human Clinical
"We propose a step-wise chart for clinical decision-making in the management and treatment of CSC."
2025 expert consensus includes focal laser photocoagulation as a treatment option for selected extrafoveal CSCR cases in its clinical decision-making algorithm.
Intravitreal Anti-VEGF Therapy
Action: intravitreal anti-VEGF injection Ontology label: Pharmacotherapy NCIT:C15986
Agent: bevacizumab NCIT:C2039 ranibizumab NCIT:C67562
Intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) are standard treatment specifically for CSCR complicated by active choroidal neovascularization (type 1 CNV). The MINERVA randomized trial supported anti-VEGF efficacy for CSC with macular neovascularization. Anti-VEGF is not effective as monotherapy for uncomplicated CSCR without CNV and meta-analyses have not confirmed efficacy in non-neovascular acute CSCR. One randomized study showed ranibizumab inferior to low-fluence PDT for anatomical outcomes in non-CNV CSCR.
Target Phenotypes: Choroidal neovascularization HP:0011506
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with intravitreal anti-vascular endothelial growth factor agents."
2025 expert consensus explicitly recommends anti-VEGF for chronic CSCR complicated by choroidal neovascularization, distinguishing this as a separate indication from PDT for non-neovascular CSCR.
🌍

Environmental Factors

3
Corticosteroid Exposure
Exogenous corticosteroid use (systemic, inhaled, intranasal, topical, epidural, or intravitreal) is the most consistently identified and strongly associated modifiable risk factor for CSCR. Corticosteroids act through mineralocorticoid receptor overstimulation in choroidal endothelial cells, amplifying hyperpermeability. Corticosteroid-associated CSCR is characterized by more severe disease with bilateral involvement, multiple RPE detachments, greater fluorescein leakage, and increased choroidal thickness. Discontinuation of corticosteroids is a key first intervention when feasible.
Show evidence (1 reference)
DOI:10.1038/s41433-025-03894-z SUPPORT Human Clinical
"Recent evidence describing the pathogenesis of and risk factors for CSC focuses on possible dysfunction of the choroid and retinal pigment epithelium, and the role of corticosteroids."
2025 international expert consensus review identifies corticosteroid exposure as the central documented modifiable risk factor, warranting its discontinuation as the first management step.
Psychosocial Stress and Type A Personality
Psychological stress and type A personality traits are associated with CSCR. Stress-driven neuroendocrine activation elevates endogenous cortisol and catecholamines, activating mineralocorticoid receptors in choroidal endothelial cells. Depression is associated with increased risk of recurrent CSCR. CSC patients demonstrate significantly poorer sleep quality (58.2% vs. 23.9% in controls). Sleep apnea is associated with approximately 5-fold increased CSCR risk. Stress reduction and sleep disorder management are recommended as supportive interventions.
Male Sex and Hormonal Factors
Male sex is a major epidemiological risk factor for CSCR, with men comprising 72–87.5% of patients. Older women show similar prevalence to men, implicating hormonal changes. High levels of glucocorticoids, mineralocorticoids, and testosterone are found in CSCR patients. Pregnancy and Cushing syndrome (excess endogenous cortisol) are associated with CSCR. Expression and splicing QTL analyses link GWAS hits to genes in genital organs, potentially contributing to sex differences in CSCR susceptibility.
Show evidence (1 reference)
DOI:10.1038/s41598-025-92210-6 SUPPORT Human Clinical
"Expression/splicing quantitative trait loci analyses showed association of identified GWAS hits with expression and/or splicing of genes in genital organs, potentially explaining the sex differences in CSCR. Men represent 72–87.5% of patients, but older women show similar prevalence rates to men."
GWAS meta-analysis identifies molecular links between CSCR risk loci and sex-specific gene expression, consistent with the strong male predominance observed epidemiologically.
🔬

Biochemical Markers

1
Serum Lipocalin 2 (LCN2/NGAL) (DECREASED)
Context: Serum LCN2 (lipocalin-2, also known as NGAL) is significantly reduced in both acute/recurrent and chronic CSCR compared to age- and sex-matched healthy controls. Low LCN2 reflects susceptibility to oxidative stress and innate immune dysregulation at the RPE level. The 80 ng/mL serum cutoff discriminates acute/recurrent CSCR from controls with 80.3% sensitivity and 75.8% specificity. Serum NGAL/MMP-9 complex is similarly reduced (cutoff 38 ng/mL, 69.6% sensitivity, 80.3% specificity). LCN2 reduction is consistent across both CSCR subtypes, providing a potential systemic biomarker link between acute and chronic disease forms.
Pathograph Readouts
Readout Of Retinal Pigment Epithelium Dysfunction Negative Diagnostic
Reduced serum LCN2 reflects systemic susceptibility to oxidative stress and innate immune dysregulation that contributes to RPE barrier failure in CSCR. Low LCN2 distinguishes CSCR patients from healthy controls and correlates with the oxidative stress component of RPE dysfunction.
Show evidence (1 reference)
DOI:10.1038/s41598-020-77202-y SUPPORT Human Clinical
"A ROC curve showed that for LCN2 serum levels, the 80-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 80.3% sensitivity and 75.8% specificity"
Case-control study in 147 CSCR patients demonstrates significantly reduced serum LCN2 across both CSCR subtypes, with an 80 ng/mL ROC cutoff providing 80.3% sensitivity and 75.8% specificity for discriminating acute/recurrent CSCR from controls.
{ }

Source YAML

click to show 
name: Central Serous Chorioretinopathy
creation_date: "2026-06-25T00:00:00Z"
category: Complex
disease_term:
  preferred_term: Central Serous Chorioretinopathy
  term:
    id: MONDO:0018616
    label: central serous chorioretinopathy
parents:
- Retinal Disorder
synonyms:
- CSCR
- central serous retinopathy
- CSC
- central serous choroidopathy
- central serous pigment epitheliopathy

description: >
  Central serous chorioretinopathy (CSCR) is a pachychoroid spectrum disorder characterized
  by focal serous detachment of the neural retina and/or retinal pigment epithelium (RPE)
  in the posterior pole, caused by choroidal hyperpermeability and RPE barrier dysfunction.
  First described by Albrecht von Graefe in 1866, CSCR predominantly affects middle-aged
  adults (peak incidence 30–50 years) with a strong male predominance (72–87.5% male).
  Acute CSCR is typically self-limiting, with spontaneous subretinal fluid (SRF) resolution
  in approximately 90–95% of cases within 2–3 months; chronic CSCR (persistent SRF
  beyond 3–4 months) causes progressive RPE decompensation, photoreceptor damage, and
  permanent vision loss in a subset. Disease etiology is complex and multifactorial:
  glucocorticoid and mineralocorticoid receptor overstimulation drives choroidal
  hyperpermeability, while GWAS loci including CFH, PTPRB, TNFRSF10A, GATA5, and NR3C2
  confer polygenic susceptibility. Half-dose verteporfin photodynamic therapy is the
  established treatment of choice for chronic CSCR.

has_subtypes:
- name: Acute CSCR
  description: >-
    Self-limiting form lasting less than 3–4 months. Subretinal fluid resolves
    spontaneously with recovery of visual acuity in approximately 90–95% of cases.
    Most common form, predominantly affecting young to middle-aged males under
    psychological or corticosteroid-related stress. Recurrence rates of 15–50%
    are observed across series.
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSCR is the first ever described pachychoroid disease. Most recently, hypothetical venous overload choroidopathy is also proposed due to its distinguished morphological and pathological characteristics, including choroidal thickening, choriocapillaris hyperpermeability, remodelling, and intervortex venous anastomoses."
    explanation: Comprehensive 2023 review documents CSCR as a pachychoroid spectrum disorder, defining its distinctive choroidal pathology relevant to both acute and chronic subtypes.

- name: Chronic CSCR
  description: >-
    Persistent form lasting more than 3–4 months, defined by continuing subretinal
    fluid with progressive RPE decompensation. Associated with diffuse RPE atrophy,
    photoreceptor outer segment disruption, and risk of choroidal neovascularization
    (CNV) in 2–15.6% of cases. Approximately 12.8% develop legal blindness after
    mean 11.3-year follow-up without treatment. Intervention with half-dose PDT is
    indicated when SRF persists beyond 3–4 months.
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability. A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with intravitreal anti-vascular endothelial growth factor agents."
    explanation: International expert consensus review distinguishes chronic CSC as requiring active treatment (PDT) and identifies CNV as a known serious complication requiring anti-VEGF.

pathophysiology:
- name: Mineralocorticoid and Glucocorticoid Receptor Overstimulation
  description: >-
    Elevated glucocorticoids and mineralocorticoids—from exogenous corticosteroid
    use, endogenous hypercortisolism, or stress-driven neuroendocrine activation—
    overstimulate mineralocorticoid receptors (MR; encoded by NR3C2) in choroidal
    endothelial cells. This upregulates vascular permeability factors, disrupts
    endothelial tight junctions, and promotes choroidal congestion. The NR3C2 gene
    is a GWAS susceptibility locus for CSCR, linking genetic predisposition to the
    glucocorticoid/mineralocorticoid axis. Corticosteroid use is the strongest and
    most consistently documented modifiable environmental risk factor for CSCR,
    producing more severe disease with higher recurrence and bilateral involvement.
  biological_processes:
  - preferred_term: glucocorticoid receptor signaling pathway
    term:
      id: GO:0042921
      label: nuclear receptor-mediated glucocorticoid signaling pathway
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent evidence describing the pathogenesis of and risk factors for CSC focuses on possible dysfunction of the choroid and retinal pigment epithelium, and the role of corticosteroids. It is suggested that CSC lies within the spectrum of pachychoroid disorders that share the characteristic of thickened choroidal tissue."
    explanation: 2025 international expert review directly implicates corticosteroids and choroid-RPE dysfunction in CSCR pathogenesis, consistent with the mineralocorticoid receptor mechanism.
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The use of oral eplerenone for routine clinical care remains controversial, and long-term randomized clinical trials are warranted to investigate its efficacy in acute and chronic CSCR."
    explanation: Review discusses mineralocorticoid receptor antagonists (eplerenone) as the direct pharmacological rationale for targeting MR overstimulation in CSCR, establishing the pathway's clinical relevance.
  downstream:
  - target: Choroidal Hyperpermeability and Pachychoroid Dysfunction
    causal_link_type: DIRECT
    description: >-
      MR overstimulation in choroidal endothelial cells upregulates vascular
      permeability factors and disrupts tight junctions, causing choroidal
      congestion and hyperpermeability.

- name: Choroidal Hyperpermeability and Pachychoroid Dysfunction
  description: >-
    The primary anatomical and vascular event in CSCR is choroidal
    hyperpermeability with thickening and dilation of the choroid, especially
    in Haller's outer vascular layer (pachyvessels). Choriocapillaris
    hyperpermeability and attenuation of the inner layers (Sattler's layer)
    follow. CSCR is classified as the first described pachychoroid spectrum
    disease, a group characterized by dilated outer choroidal vessels driving
    pressure-mediated choriocapillaris dysfunction. Intervortex venous anastomoses
    and choroidal venous congestion may reflect underlying vascular endothelial
    phosphatase (VE-PTP; PTPRB) dysfunction and abnormal choroidal venous drainage,
    supporting the recently proposed "venous overload choroidopathy" hypothesis.
  cell_types:
  - preferred_term: choroidal endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: positive regulation of vascular permeability
    term:
      id: GO:0043117
      label: positive regulation of vascular permeability
    modifier: INCREASED
  - preferred_term: blood vessel remodeling
    term:
      id: GO:0001974
      label: blood vessel remodeling
    modifier: ABNORMAL
  locations:
  - preferred_term: choroid
    term:
      id: UBERON:0001776
      label: optic choroid
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSCR is the first ever described pachychoroid disease. Most recently, hypothetical venous overload choroidopathy is also proposed due to its distinguished morphological and pathological characteristics, including choroidal thickening, choriocapillaris hyperpermeability, remodelling, and intervortex venous anastomoses."
    explanation: Landmark 2023 review establishes choroidal hyperpermeability and pachychoroid anatomy as the defining pathological feature of CSCR and introduces the venous overload choroidopathy model.
  - reference: DOI:10.1038/s41467-025-58686-6
    reference_title: "Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The rs113791087 missense variant in PTPRB encoding vascular endothelial protein tyrosine phosphatase (VE-PTP) confers OR = 3.06 (P = 7.4 x 10^-15) in a meta-analysis of 2,452 CSC patients and 865,767 controls across four studies, and abnormal choroidal veins in CSC patients share morphological similarities with varicose veins."
    explanation: 2025 Nature Communications study identifies VE-PTP (PTPRB) as the strongest single-variant risk factor for CSCR, directly linking vascular endothelial phosphatase dysfunction to choroidal venous pathology.
  downstream:
  - target: Retinal Pigment Epithelium Dysfunction
    causal_link_type: DIRECT
    description: >-
      Increased hydrostatic pressure from congested choroidal vessels overwhelms
      RPE pump capacity and tight junction integrity, causing focal RPE breakdown
      and sub-RPE fluid accumulation.

- name: Complement Factor H Pathway Dysregulation
  description: >-
    Genetic variation at the CFH locus (1q31.3) is among the most consistently
    replicated susceptibility signals for CSCR across multiple GWAS. Complement
    factor H (CFH) and its related proteins (CFHR1-5) regulate the alternative
    complement pathway through competition for C3b binding. GWAS meta-analyses
    identify 26 CFH- or CFHR-related biological pathways with genome-wide
    significant associations with CSCR susceptibility. Protein quantitative trait
    loci analyses support protein-level contribution of the CFH pathway to CSCR
    pathogenesis. The mechanism likely involves local complement dysregulation in
    the choroidal-RPE interface, driving tissue damage and chronic vascular
    inflammation, in parallel with the mineralocorticoid pathway.
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1038/s41598-025-92210-6
    reference_title: "Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A meta-analysis of three GWAS comprising 8,811 Asians and Caucasians with replication in 4,338 additional Asians identified seven genome-wide significant loci including CFH, TNFRSF10A, GATA5, CDH5, and VIPR2, with 26 CFH- or CFHR-related pathways showing significant associations indicating the complement pathway's importance in CSCR pathogenesis."
    explanation: 2025 multi-ethnic GWAS meta-analysis identifies CFH-pathway dysregulation as a central genetic mechanism in CSCR, supported by protein QTL and pathway enrichment analyses.
  - reference: DOI:10.1016/j.xops.2025.101043
    reference_title: "The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The CFH rs1329428 variant showed significant association with chronic CSCR with macular neovascularization, and 26 CFH- or CFHR-related pathways were significantly associated in GWAS analyses."
    explanation: 2026 multi-disease genetic study confirms the CFH-CFHR5 locus as a shared risk factor across pachychoroid spectrum disorders, with particular relevance to chronic CSCR with neovascular complications.
  downstream:
  - target: Retinal Pigment Epithelium Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Complement dysregulation at the choroid-RPE interface promotes local
      inflammation and tissue injury, compounding the hydrostatic stress from
      choroidal hyperpermeability to drive RPE decompensation.
    intermediate_mechanisms:
    - Complement-mediated choroidal inflammation and vascular injury
    - Increased choroidal vascular permeability

- name: Retinal Pigment Epithelium Dysfunction
  description: >-
    Hydrostatic and complement-mediated stress from the congested pachychoroid leads
    to focal RPE breakdown. RPE cells lose tight junction integrity and ion transport
    function, allowing fluid to leak through focal RPE defects into the subretinal
    space, visible as fluorescein angiography leakage points. In acute CSCR, single
    focal leaks predominate; in chronic CSCR, diffuse RPE atrophy and decompensation
    develop. Reduced serum lipocalin 2 (LCN2/NGAL) in CSCR patients reflects
    susceptibility to excessive oxidative stress and innate immune dysregulation,
    compounding RPE barrier failure.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: monoatomic ion transport
    term:
      id: GO:0006811
      label: monoatomic ion transport
    modifier: DECREASED
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1038/s41598-020-77202-y
    reference_title: "Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In both acute and chronic CSCR, low serum LCN2 and NGAL/MMP-9, provide a biological link between the two CSCR forms, and potential susceptibility to oxidative stress and innate immune dysregulation in CSCR."
    explanation: Case-control study in 147 CSCR patients demonstrates significantly reduced serum LCN2 across both CSCR subtypes, implicating oxidative stress susceptibility and innate immune dysregulation as contributors to RPE barrier failure.
  downstream:
  - target: Subretinal Fluid Accumulation and Photoreceptor Injury
    causal_link_type: DIRECT
    description: >-
      Focal RPE breakdown allows transudation of fluid from the sub-RPE space
      into the subretinal compartment, creating the neurosensory retinal
      detachment that is the defining anatomical lesion of CSCR.

- name: Subretinal Fluid Accumulation and Photoreceptor Injury
  description: >-
    Fluid accumulation beneath the neurosensory retina separates the photoreceptor
    layer from the RPE, disrupting outer segment renewal, nutritional exchange,
    and visual signal transduction. Photoreceptor outer segments elongate
    abnormally in response to subretinal fluid; the ellipsoidal zone (EZ) band
    disruption on OCT correlates directly with visual acuity loss. Prolonged
    detachment in chronic CSCR leads to progressive photoreceptor atrophy,
    ganglion cell loss, and permanent visual impairment. Choroidal
    neovascularization (CNV; type 1) develops in 2–15.6% of chronic CSCR eyes
    and further threatens visual prognosis. Legal blindness develops in
    approximately 12.8% of patients after mean 11.3-year follow-up.
  cell_types:
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: DECREASED
  - preferred_term: positive regulation of angiogenesis
    term:
      id: GO:0045766
      label: positive regulation of angiogenesis
    modifier: INCREASED
  locations:
  - preferred_term: macula lutea
    term:
      id: UBERON:0000053
      label: macula lutea
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Half-dose photodynamic therapy (PDT) remains the mainstay of clinical practice, with about 95% of patients with chronic CSCR improving to visual acuity (VA) of 20/30 or better."
    explanation: Comprehensive review documents the visual prognosis of chronic CSCR with and without treatment, confirming subretinal fluid-driven photoreceptor injury as the primary determinant of visual outcomes.

environmental:
- name: Corticosteroid Exposure
  notes: >
    Exogenous corticosteroid use (systemic, inhaled, intranasal, topical, epidural,
    or intravitreal) is the most consistently identified and strongly associated
    modifiable risk factor for CSCR. Corticosteroids act through mineralocorticoid
    receptor overstimulation in choroidal endothelial cells, amplifying
    hyperpermeability. Corticosteroid-associated CSCR is characterized by more
    severe disease with bilateral involvement, multiple RPE detachments, greater
    fluorescein leakage, and increased choroidal thickness. Discontinuation of
    corticosteroids is a key first intervention when feasible.
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent evidence describing the pathogenesis of and risk factors for CSC focuses on possible dysfunction of the choroid and retinal pigment epithelium, and the role of corticosteroids."
    explanation: 2025 international expert consensus review identifies corticosteroid exposure as the central documented modifiable risk factor, warranting its discontinuation as the first management step.

- name: Psychosocial Stress and Type A Personality
  notes: >
    Psychological stress and type A personality traits are associated with CSCR.
    Stress-driven neuroendocrine activation elevates endogenous cortisol and
    catecholamines, activating mineralocorticoid receptors in choroidal
    endothelial cells. Depression is associated with increased risk of recurrent
    CSCR. CSC patients demonstrate significantly poorer sleep quality (58.2%
    vs. 23.9% in controls). Sleep apnea is associated with approximately
    5-fold increased CSCR risk. Stress reduction and sleep disorder management
    are recommended as supportive interventions.

- name: Male Sex and Hormonal Factors
  notes: >
    Male sex is a major epidemiological risk factor for CSCR, with men comprising
    72–87.5% of patients. Older women show similar prevalence to men, implicating
    hormonal changes. High levels of glucocorticoids, mineralocorticoids, and
    testosterone are found in CSCR patients. Pregnancy and Cushing syndrome (excess
    endogenous cortisol) are associated with CSCR. Expression and splicing QTL
    analyses link GWAS hits to genes in genital organs, potentially contributing
    to sex differences in CSCR susceptibility.
  evidence:
  - reference: DOI:10.1038/s41598-025-92210-6
    reference_title: "Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Expression/splicing quantitative trait loci analyses showed association of identified GWAS hits with expression and/or splicing of genes in genital organs, potentially explaining the sex differences in CSCR. Men represent 72–87.5% of patients, but older women show similar prevalence rates to men."
    explanation: GWAS meta-analysis identifies molecular links between CSCR risk loci and sex-specific gene expression, consistent with the strong male predominance observed epidemiologically.

phenotypes:
- name: Blurred Central Vision
  description: >-
    The cardinal symptom of CSCR. Subretinal fluid beneath the macula displaces
    and distorts the overlying photoreceptors, causing reduction in best-corrected
    visual acuity. Visual acuity typically ranges from 20/20 to 20/200 depending
    on the degree and duration of detachment. In acute CSCR, spontaneous recovery
    to 20/20 is expected in 90-95% of cases; in chronic CSCR, permanent acuity
    loss is common.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet defines blurred vision as a cardinal symptom of CSCR, consistent with subretinal fluid-mediated photoreceptor displacement as the defining pathological feature.

- name: Metamorphopsia
  description: >-
    Distortion of straight lines is a very frequent complaint due to physical
    displacement of photoreceptors by the subretinal fluid dome. Patients report
    that straight lines appear wavy or bent on Amsler grid testing. Metamorphopsia
    may persist even after SRF resolution due to photoreceptor realignment changes.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Metamorphopsia
    term:
      id: HP:0012508
      label: Metamorphopsia
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet record lists metamorphopsia as a defining symptom of CSCR, caused by photoreceptor displacement from subretinal fluid accumulation under the macula.

- name: Relative Central Scotoma
  description: >-
    A relative (not absolute) dark spot in the center of vision corresponding
    to the region of macular detachment. Caused by photoreceptor outer segment
    dysfunction in the elevated subretinal fluid zone. May become denser or more
    absolute in chronic CSCR with progressive photoreceptor loss.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Central scotoma
    term:
      id: HP:0000603
      label: Central scotoma
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet record explicitly lists relative central scotoma as a defining symptom, reflecting the focal macular subretinal fluid accumulation that characterizes CSCR.

- name: Hypermetropic Shift
  description: >-
    The elevation of the retina by subretinal fluid effectively shortens the
    optical path, causing a transient hypermetropic (far-sighted) shift.
    This results in reduced near vision and may initially lead patients to
    seek spectacle correction rather than ophthalmological evaluation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hyperopia
    term:
      id: HP:0000540
      label: Hypermetropia
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet record includes hypermetropization (hypermetropic shift) as a characteristic symptom of CSCR, reflecting the refractive effect of retinal elevation by subretinal fluid.

- name: Reduced Contrast Sensitivity
  description: >-
    Patients with CSCR commonly experience reduced ability to distinguish subtle
    differences in shading, even when formal visual acuity testing is near-normal.
    Contrast sensitivity testing may reveal significant dysfunction not captured
    by standard Snellen acuity, and this deficiency often persists beyond SRF
    resolution.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Reduced contrast sensitivity
    term:
      id: HP:0032036
      label: Reduced contrast sensitivity
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet record lists reduced contrast sensitivity as a defining feature of CSCR, consistent with photoreceptor outer segment dysfunction in the detached macula.

- name: Photopsia
  description: >-
    Brief flashes of light experienced by some CSCR patients due to mechanical
    stimulation of photoreceptors by shifting subretinal fluid. Less consistent
    than metamorphopsia or central scotoma, but may be an early symptom.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Photopsia
    term:
      id: HP:0030786
      label: Photopsia

- name: Macular Atrophy
  description: >-
    A complication of chronic or recurrent CSCR in which prolonged photoreceptor
    separation from the RPE leads to irreversible outer retinal and RPE cell loss.
    Fundus autofluorescence shows hypoautofluorescent atrophic zones. Macular
    atrophy is associated with the "descending tracts" appearance of gravitational
    chronic subretinal fluid in more severe cases. Represents permanent structural
    damage and a major cause of irreversible vision loss in chronic CSCR.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Macular atrophy
    term:
      id: HP:0007401
      label: Macular atrophy

- name: Choroidal Neovascularization
  description: >-
    Type 1 (sub-RPE) choroidal neovascularization develops as a complication of
    chronic CSCR in 2–15.6% of patients, likely driven by chronic RPE stress and
    VEGF upregulation. Detected by OCT angiography as abnormal flow in the
    sub-RPE space. Presence of CNV worsens prognosis and changes treatment
    strategy to require intravitreal anti-VEGF therapy.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with intravitreal anti-vascular endothelial growth factor agents."
    explanation: 2025 consensus review identifies CNV as a documented complication of chronic CSCR requiring anti-VEGF therapy, distinct from the choroidal hyperpermeability managed with PDT.

- name: Dyschromatopsia
  description: >-
    Moderate color vision impairment is a documented symptom of CSCR, caused by
    dysfunction of cone photoreceptors in the detached macula. Subretinal fluid
    disrupts the photoreceptor outer segment-RPE interface required for chromophore
    regeneration and cone signal fidelity, resulting in reduced color discrimination.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dyschromatopsia
    term:
      id: HP:0007641
      label: Dyschromatopsia
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet explicitly lists moderate dyschromatopsia as a characteristic symptom of CSCR, consistent with cone photoreceptor dysfunction from subretinal fluid in the macula.

- name: Micropsia
  description: >-
    Perception that objects appear smaller than their actual size, caused by
    physical displacement and spreading of cone photoreceptors by the subretinal
    fluid dome. Occurs when the macula is elevated, increasing the angular spacing
    between photoreceptors. May be confused with or co-occur with metamorphopsia.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Micropsia
    term:
      id: HP:0012508
      label: Metamorphopsia
  evidence:
  - reference: ORPHA:443079
    reference_title: "Central serous chorioretinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms tend to include blurred or distorted vision (metamorphopsia), moderate dyschromatopsia, relative central scotoma, hypermetropization, micropsia and reduced contrast sensitivity."
    explanation: Orphanet explicitly lists micropsia as a symptom of CSCR, distinct from metamorphopsia, caused by photoreceptor displacement and spreading by the subretinal fluid dome.

treatments:
- name: Observation and Risk Factor Modification
  description: >-
    First-line approach for acute CSCR, as approximately 90–95% of cases
    spontaneously resolve within 2–3 months. Observation includes: discontinuation
    of corticosteroids when possible, management of psychosocial stress, treatment
    of obstructive sleep apnea, and close monitoring with OCT and visual acuity
    assessments at 4–6 week intervals. Intervention is considered if SRF persists
    beyond 3–4 months or if the patient has special visual demands. Recurrence rates
    remain 15–50% after resolution, higher without treatment.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We propose a step-wise chart for clinical decision-making in the management and treatment of CSC. New data on long-term visual outcomes and the pathogenesis of CSC in relation to the pachychoroid disease spectrum provide a better understanding to inform our management of this disease."
    explanation: 2025 international expert consensus proposes a step-wise management algorithm in which observation with risk factor modification is the initial strategy for uncomplicated acute CSCR.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment

- name: Half-Dose Verteporfin Photodynamic Therapy
  description: >-
    Half-dose (3 mg/m² instead of 6 mg/m²) photodynamic therapy with verteporfin
    is the established treatment of choice for chronic CSCR. Verteporfin selectively
    accumulates in abnormal choroidal vessels; laser activation at 689 nm induces
    choriocapillaris vascular remodeling, reducing choroidal hyperpermeability and
    subretinal fluid accumulation. Half-dose protocol minimizes RPE damage compared
    to standard PDT. SRF resolution rates exceed 91% at 19 months; approximately
    95% of treated patients achieve VA of 20/30 or better. PDT reduces recurrence
    to approximately 20% versus 53.8% with observation alone. The PLACE randomized
    trial demonstrated superiority of half-dose PDT over high-density subthreshold
    micropulse laser in chronic CSCR. Half-fluence PDT is an alternative reduced
    dosing strategy with comparable safety.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Photodynamic therapy
    term:
      id: NCIT:C15300
      label: Photodynamic Therapy
    therapeutic_agent:
    - preferred_term: verteporfin
      term:
        id: CHEBI:32293
        label: verteporfin
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Half-dose photodynamic therapy (PDT) remains the mainstay of clinical practice, with about 95% of patients with chronic CSCR improving to visual acuity (VA) of 20/30 or better."
    explanation: Comprehensive 2023 review establishes half-dose PDT as the mainstay treatment for chronic CSCR, with approximately 95% of patients achieving VA 20/30 or better.
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability."
    explanation: 2025 international expert consensus review recommends half-dose/half-fluence PDT as the treatment of choice for CSCR, targeting the underlying choroidal hyperpermeability.
  target_mechanisms:
  - target: Choroidal Hyperpermeability and Pachychoroid Dysfunction
    treatment_effect: INHIBITS
    description: >-
      Verteporfin PDT causes targeted choriocapillaris occlusion and remodeling
      of abnormal choroidal vessels, normalizing choroidal permeability and
      reducing subretinal fluid generation.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment

- name: Mineralocorticoid Receptor Antagonists
  description: >-
    Eplerenone and spironolactone, oral mineralocorticoid receptor antagonists,
    were investigated as pharmacological treatments targeting the MR/cortisol
    pathway implicated in CSCR pathogenesis. The VICI randomized controlled trial
    (eplerenone vs. placebo in chronic CSCR) failed to meet its primary endpoint
    of improving best-corrected visual acuity at 12 months. Despite mechanistic
    rationale and early observational evidence, eplerenone did not demonstrate
    significant benefit over placebo for visual acuity in this pivotal trial. Routine
    use for chronic CSCR remains controversial; these agents may be considered when
    PDT is unavailable or contraindicated, but are not a substitute for PDT. Long-term
    RCT data are warranted before routine clinical adoption.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: eplerenone
      term:
        id: CHEBI:31547
        label: eplerenone
    - preferred_term: spironolactone
      term:
        id: CHEBI:9241
        label: spironolactone
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The use of oral eplerenone for routine clinical care remains controversial, and long-term randomized clinical trials are warranted to investigate its efficacy in acute and chronic CSCR."
    explanation: 2023 comprehensive review explicitly states eplerenone's routine use remains controversial after the VICI trial failed to demonstrate BCVA benefit, cautioning against its adoption as standard care.
  target_mechanisms:
  - target: Mineralocorticoid and Glucocorticoid Receptor Overstimulation
    treatment_effect: INHIBITS
    description: >-
      MR antagonists block mineralocorticoid receptor signaling in choroidal
      endothelial cells, theoretically reducing vascular permeability; however,
      clinical benefit in BCVA was not demonstrated in the VICI RCT.

- name: Subthreshold Micropulse Laser
  description: >-
    High-density subthreshold micropulse laser (577 nm HSML) delivers
    sub-lethal retinal laser energy to stimulate RPE function without causing
    visible burns. Complete SRF resolution rates range from 36–100% across
    studies. The PLACE randomized trial demonstrated that half-dose PDT was
    superior to high-density micropulse laser for chronic CSCR in SRF
    resolution rate and recurrence. Micropulse laser is a reasonable alternative
    when PDT is unavailable, contraindicated, or for extrafoveal leakage, but
    should not be preferred over PDT for chronic subfoveal CSCR.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Laser therapy
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Available evidence supports half-dose (or half-fluence) verteporfin photodynamic therapy as the treatment of choice for CSC to reduce choroidal hyperpermeability."
    explanation: 2025 expert review recommends PDT as the treatment of choice over micropulse laser, citing the PLACE trial results showing PDT superiority; micropulse is an acceptable but less effective alternative.
  target_mechanisms:
  - target: Retinal Pigment Epithelium Dysfunction
    treatment_effect: INHIBITS
    description: >-
      Subthreshold micropulse laser delivers sub-lethal thermal energy to the
      RPE, stimulating RPE cell function and reducing focal leakage without
      causing visible RPE burns or permanent tissue destruction.

- name: Focal Laser Photocoagulation
  description: >-
    Focal laser photocoagulation of the leakage point(s) identified on
    fluorescein angiography can accelerate SRF resolution in acute CSCR with
    extrafoveal focal leakage. Not appropriate for subfoveal or juxtafoveal
    leaks due to risk of causing permanent scotoma. Historical 5-year data
    suggest fewer recurrences and better VA than observation in some studies.
    Less commonly used since PDT has demonstrated superior outcomes for chronic
    and subfoveal CSCR.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Laser photocoagulation
    term:
      id: NCIT:C62730
      label: Infrared Photocoagulation Therapy
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "We propose a step-wise chart for clinical decision-making in the management and treatment of CSC."
    explanation: 2025 expert consensus includes focal laser photocoagulation as a treatment option for selected extrafoveal CSCR cases in its clinical decision-making algorithm.
  target_mechanisms:
  - target: Retinal Pigment Epithelium Dysfunction
    treatment_effect: INHIBITS
    description: >-
      Focal laser photocoagulation creates a controlled thermal burn at the
      focal RPE leakage point identified on fluorescein angiography, sealing
      the defect and halting subretinal fluid transudation. Restricted to
      extrafoveal leaks to avoid central scotoma.

- name: Intravitreal Anti-VEGF Therapy
  description: >-
    Intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) are
    standard treatment specifically for CSCR complicated by active choroidal
    neovascularization (type 1 CNV). The MINERVA randomized trial supported
    anti-VEGF efficacy for CSC with macular neovascularization. Anti-VEGF is not
    effective as monotherapy for uncomplicated CSCR without CNV and meta-analyses
    have not confirmed efficacy in non-neovascular acute CSCR. One randomized
    study showed ranibizumab inferior to low-fluence PDT for anatomical outcomes
    in non-CNV CSCR.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: intravitreal anti-VEGF injection
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bevacizumab
      term:
        id: NCIT:C2039
        label: Bevacizumab
    - preferred_term: ranibizumab
      term:
        id: NCIT:C67562
        label: Ranibizumab
  evidence:
  - reference: DOI:10.1038/s41433-025-03894-z
    reference_title: "Treatment of central serous chorioretinopathy: new options for an old disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A subset of patients with chronic CSC can develop choroidal neovascularisation, and these patients should be treated with intravitreal anti-vascular endothelial growth factor agents."
    explanation: 2025 expert consensus explicitly recommends anti-VEGF for chronic CSCR complicated by choroidal neovascularization, distinguishing this as a separate indication from PDT for non-neovascular CSCR.
  target_phenotypes:
  - preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization

diagnosis:
- name: Optical Coherence Tomography
  description: >-
    OCT is the primary diagnostic modality for CSCR, demonstrating subretinal
    fluid (SRF) as an optically clear space between the neurosensory retina and
    the RPE. Enhanced depth imaging OCT (EDI-OCT) additionally reveals
    subfoveal choroidal thickening (pachychoroid), pigment epithelial
    detachments (PEDs), and disruption of the ellipsoidal zone band correlating
    with visual acuity loss. OCT-A (angiography) detects choroidal
    neovascularization at the level of the choriocapillaris as an abnormal flow
    signal. OCT is used for diagnosis, monitoring SRF resolution, and treatment
    response assessment.
  diagnosis_term:
    preferred_term: optical coherence tomography
    term:
      id: MAXO:0000969
      label: optical coherence tomography
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The novel multimodality imaging platforms, including the ultra-widefield imaging system, flavoprotein fluorescence, fluorescence lifetime imaging ophthalmoscopy, and multispectral imaging system, have been used for diagnosing and managing CSCR."
    explanation: >-
      2023 comprehensive review establishes multimodality imaging—anchored by OCT—as the
      standard for diagnosing CSCR and assessing treatment response; OCT identifies
      SRF, PEDs, choroidal thickening, and CNV.

- name: Fluorescein Angiography
  description: >-
    Fluorescein angiography (FA) demonstrates the characteristic inkblot or
    smokestack pattern of focal RPE leakage in CSCR. The smokestack pattern
    (ascending and expanding dye column) is pathognomonic for acute CSCR;
    inkblot (radially expanding fluorescence) is more common. FA defines the
    leakage point for focal laser treatment planning. In chronic CSCR, diffuse
    RPE decompensation produces multiple, ill-defined leakage zones.
  diagnosis_term:
    preferred_term: fluorescein angiography
    term:
      id: MAXO:0035003
      label: fluorescein angiography
  evidence:
  - reference: DOI:10.1186/s40662-023-00349-y
    reference_title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The novel multimodality imaging platforms, including the ultra-widefield imaging system, flavoprotein fluorescence, fluorescence lifetime imaging ophthalmoscopy, and multispectral imaging system, have been used for diagnosing and managing CSCR."
    explanation: >-
      Multimodality imaging review covers FA as an established modality for CSCR;
      FA identifies focal RPE leakage points required for treatment planning and
      characterizes the smokestack or inkblot leakage patterns pathognomonic for
      acute CSCR.

biochemical:
- name: Serum Lipocalin 2 (LCN2/NGAL)
  presence: DECREASED
  context: >-
    Serum LCN2 (lipocalin-2, also known as NGAL) is significantly reduced in
    both acute/recurrent and chronic CSCR compared to age- and sex-matched
    healthy controls. Low LCN2 reflects susceptibility to oxidative stress and
    innate immune dysregulation at the RPE level. The 80 ng/mL serum cutoff
    discriminates acute/recurrent CSCR from controls with 80.3% sensitivity
    and 75.8% specificity. Serum NGAL/MMP-9 complex is similarly reduced
    (cutoff 38 ng/mL, 69.6% sensitivity, 80.3% specificity). LCN2 reduction
    is consistent across both CSCR subtypes, providing a potential systemic
    biomarker link between acute and chronic disease forms.
  readouts:
  - target: Retinal Pigment Epithelium Dysfunction
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Reduced serum LCN2 reflects systemic susceptibility to oxidative stress
      and innate immune dysregulation that contributes to RPE barrier failure in
      CSCR. Low LCN2 distinguishes CSCR patients from healthy controls and
      correlates with the oxidative stress component of RPE dysfunction.
    evidence:
    - reference: DOI:10.1038/s41598-020-77202-y
      reference_title: "Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A ROC curve showed that for LCN2 serum levels, the 80-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 80.3% sensitivity and 75.8% specificity"
      explanation: >-
        Case-control study in 147 CSCR patients demonstrates significantly reduced
        serum LCN2 across both CSCR subtypes, with an 80 ng/mL ROC cutoff providing
        80.3% sensitivity and 75.8% specificity for discriminating acute/recurrent
        CSCR from controls.

discussions:
- discussion_id: gap_cscr_pachychoroid_animal_model_mismatch
  prompt: >-
    Do available animal models (aldosterone-induced rat, choroidal congestion mouse,
    adrenaline-induced rabbit) faithfully reproduce the human CSCR pachychoroid
    phenotype—with its distinctive dilated Haller's layer vessels, choriocapillaris
    attenuation, and RPE focal breakdown driven by chronic venous congestion—or does
    the absence of a pachychoroid anatomical substrate in rodents and lagomorphs mean
    that these models address only individual upstream triggers (hormonal, vascular
    congestion) rather than the full human disease spectrum?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Choroidal Hyperpermeability and Pachychoroid Dysfunction
  - pathophysiology#Mineralocorticoid and Glucocorticoid Receptor Overstimulation
  rationale: >-
    Current animal models recapitulate specific upstream mechanisms: aldosterone
    treatment in rats produces subretinal fluid and RPE changes consistent with
    mineralocorticoid receptor overstimulation, and choroidal congestion mouse
    models address some aspects of vascular hyperpermeability. However, no animal
    species possesses a pachychoroid anatomy (thickened choroid with enlarged Haller's
    layer vessels and attenuated choriocapillaris) homologous to the human lesion.
    The genetic risk architecture—particularly CFH pathway and PTPRB variants—is
    not modeled by any existing system. This mismatch limits translational inference:
    pharmacological effects shown in rodent models (e.g., melatonin preventing
    aldosterone-induced SRF in rats) may not reflect efficacy against the full
    human pachychoroid disease. Validating the PTPRB-VE-PTP and CFH mechanisms
    requires species with relevant choroidal anatomy or humanized vascular
    endothelial systems.
  proposed_experiments:
  - experiment_id: exp_cscr_primate_pachychoroid
    name: Non-human primate model with pachychoroid-like anatomy for CSCR validation
    description: >-
      Identify or induce a pachychoroid phenotype in macaques or marmosets
      (which have thicker choroids than rodents) via aldosterone + corticosteroid
      exposure to test whether the mineralocorticoid receptor and PTPRB pathways
      operate in a choroidal vascular bed more analogous to the human CSCR substrate.

references:
- reference: ORPHA:443079
  title: "Central serous chorioretinopathy"
- reference: DOI:10.1186/s40662-023-00349-y
  title: "Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies"
- reference: DOI:10.1038/s41433-025-03894-z
  title: "Treatment of central serous chorioretinopathy: new options for an old disease"
- reference: DOI:10.1038/s41598-025-92210-6
  title: "Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy"
- reference: DOI:10.1038/s41467-025-58686-6
  title: "Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma"
- reference: DOI:10.1038/s41598-020-77202-y
  title: "Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy"
- reference: DOI:10.1016/j.xops.2025.101043
  title: "The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy"
📚

References & Deep Research

References

7
ORPHA:443079
Central serous chorioretinopathy
No top-level findings curated for this source.
DOI:10.1186/s40662-023-00349-y
Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies
No top-level findings curated for this source.
DOI:10.1038/s41433-025-03894-z
Treatment of central serous chorioretinopathy: new options for an old disease
No top-level findings curated for this source.
DOI:10.1038/s41598-025-92210-6
Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy
No top-level findings curated for this source.
DOI:10.1038/s41467-025-58686-6
Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma
No top-level findings curated for this source.
DOI:10.1038/s41598-020-77202-y
Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy
No top-level findings curated for this source.
DOI:10.1016/j.xops.2025.101043
The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy
No top-level findings curated for this source.

Deep Research

2
Claude Code ▸
CSCR Research Report
claude-haiku-4-5-20251001, claude-sonnet-4-6 2026-06-25T12:17:28.082107

CSCR Research Report

Important: All PMIDs below are from training knowledge and must be verified with just fetch-reference PMID:XXXXX before writing any snippet into the YAML. Priority fetch list is at the end.

1. Disease Information

Field Value
MONDO MONDO:0018616
ORPHA ORPHA:443079
ICD-10 H35.7
ICD-11 9B75.2
MeSH D056833
UMLS C0730328
OMIM No single entry — complex/multifactorial, no classic Mendelian form
MedDRA 10086644

Synonyms: Central serous retinopathy (CSR), CSCR, CSC, central serous chorioretinitis (historical), idiopathic central serous chorioretinopathy.

CSCR is classified by Orphanet as a rare choroidal disorder, but is actually the fourth most common retinal disorder in adults after AMD, diabetic retinopathy, and branch retinal vein occlusion — particularly prevalent in young to middle-aged males.

2. Etiology & Risk Factors

Genetic Risk Factors (GWAS findings)

Gene/Locus Variant OR PMID
CFH (1q32) rs800292 (I62V) ~1.6–1.8 PMID:25939894
CFH (1q32) rs1061170 (Y402H) ~1.4 PMID:25939894
ARMS2/HTRA1 (10q26) rs10490924 ~1.4 PMID:29515099
NR3C2 (4q31.1) regulatory variant — PMID:34385711
KCNJ13 (2q37) regulatory variant — PMID:34385711
GATA5 (18q11.2) rs6141806 — PMID:31712692

Key point: CFH and ARMS2/HTRA1 are the same loci associated with AMD — CSCR and AMD share genetic architecture at Bruch membrane/choroidal vascular vulnerability genes.

Environmental Risk Factors

  • Corticosteroids (strongest modifiable risk): ~10–40× increased risk; all routes (systemic > intranasal > inhaled > topical skin > epidural). Even brief high-dose burst courses are sufficient. PMID:25654734 (pharmacoepidemiology), PMID:17702499 (review).
  • Psychosocial stress / Type A personality: Chronic HPA axis activation → elevated cortisol → MR activation. PMID:15897545.
  • Obstructive sleep apnea: OR ~2–4; intermittent hypoxia + cortisol dysregulation. PMID:23736878.
  • Pregnancy: Third trimester; elevated placental CRH and cortisol. Usually resolves postpartum. PMID:8778938.
  • H. pylori: Multiple case-control studies show association; eradication may help but data conflicting. Controversial.
  • Endogenous Cushing syndrome: CSCR can be the presenting feature — check cortisol in severe/bilateral cases.

Mineralocorticoid Receptor Pathway (detailed mechanism)

In choroidal endothelial cells, 11β-HSD2 expression is low, so cortisol is not inactivated locally and freely activates NR3C2 (mineralocorticoid receptor): 1. MR nuclear translocation → upregulates VEGF-A → VEGFR2 phosphorylation of VE-cadherin → junction opening → hyperpermeability 2. Upregulates AQP1 (aquaporin-1) → increased transendothelial water flux 3. Upregulates SERPINE1 (PAI-1) → fibrin deposition in choroid 4. Downregulates tight junction proteins (occludin, claudin-5)

Seminal mechanistic paper: PMID:22446627 (Zhao et al. 2012, J Clin Invest — mineralocorticoid receptor in rat and human chorioretinopathy).

3. Phenotypes (with HPO terms and frequencies)

Phenotype HPO Term Frequency Clinical Details
Visual impairment / blurred central vision HP:0000505 VERY_FREQUENT (>90%) VA 20/20 to 20/200; often mild in acute
Metamorphopsia HP:0012508 FREQUENT (60–80%) Wavy/distorted lines; Amsler grid test
Micropsia HP:0012508 (best fit) / HP:0000505 FREQUENT (50–70%) Objects appear smaller; photoreceptor displacement
Relative central scotoma HP:0000575 FREQUENT (60–80%) Relative, not absolute
Reduced contrast sensitivity HP:0007663 FREQUENT (60–80%) Often disproportionate to Snellen acuity
Hypermetropic shift HP:0000540 FREQUENT (>70%) 0.5–2.0 diopters; retinal elevation shortens focal length
Dyschromatopsia / color vision deficit HP:0000551 OCCASIONAL (30–50%) Blue-yellow axis; Farnsworth-Munsell testing
Photopsia HP:0030786 OCCASIONAL (20–40%) Brief flashes; mechanical photoreceptor stimulation
Nyctalopia / impaired dark adaptation HP:0000662 OCCASIONAL (20–40%) Especially in chronic CSCR with rod involvement
Abnormal multifocal ERG HP:0000580 FREQUENT in chronic Reduced macular responses; central P1 amplitude

Note on micropsia: Orphanet explicitly lists micropsia as a CSCR symptom (ORPHA:443079 definition). HPO:HP:0012508 (Metamorphopsia) is the closest; add preferred_term "Micropsia" with a note. Consider also HP:0012508 with a modifier.

Subtype-specific notes: - Acute CSCR: Acute monocular onset; VA often 20/30–20/60; spontaneous improvement expected - Chronic CSCR: Bilateral in ~40%; "descending RPE tracks" (gravity-dependent atrophy); cystoid macular degeneration; subretinal fibrin/precipitates; choroidal neovascularization

4. Genetics / Molecular (detailed)

CFH polymorphisms

  • rs800292 (I62V): Risk allele reduces CFH's C3b binding and factor I cofactor activity → less complement regulation at choroidal Bruch membrane → C5a-mediated mast cell degranulation → histamine → permeability increase
  • rs1061170 (Y402H): Reduces CFH binding to heparan sulfate in choroid → impaired local complement regulation

Key GWAS papers

  1. PMID:25939894 — Schellevis 2015, J Med Genet: First CSCR GWAS (170 cases); CFH rs800292 genome-wide significant (OR 1.59)
  2. PMID:29515099 — Schellevis 2018, Ophthalmology: Expanded GWAS (~750 cases); confirmed CFH + new hit ARMS2/HTRA1 (rs10490924, OR 1.38)
  3. PMID:31712692 — Hosoda 2020, Japanese GWAS: GATA5 locus; pachychoroid disease spectrum
  4. PMID:34385711 — Large European meta-GWAS (>4,200 cases): confirmed CFH, ARMS2/HTRA1; novel hits NR3C2, KCNJ13 (verify this PMID)

NR3C2 variants

GWAS signal is regulatory (non-coding). Rare gain-of-function NR3C2 coding variants reported in familial CSCR cases. Supports constitutive MR hyperactivity as genetic risk mechanism.

KCNJ13

Encodes Kir7.1 inwardly rectifying potassium channel in RPE basolateral membrane. Coding mutations cause Leber congenital amaurosis (monogenic). GWAS variants in CSCR suggest subtler RPE ion transport dysregulation.

No monogenic/Mendelian form established. No CNV/chromosomal abnormalities implicated.

5. Pathophysiology (Detailed Causal Chain)

Node 1: Choroidal Hyperpermeability and Pachychoroid Phenotype

Cell type: CL:0000115 (endothelial cell; preferred_term "choroidal endothelial cell") Biological processes: - GO:0043117 (positive regulation of vascular permeability) — INCREASED - GO:0042921 (glucocorticoid receptor signaling pathway) - GO:0045944 (positive regulation of transcription by RNA polymerase II) — MR-mediated

Pachychoroid structural predisposition: - Dilated outer choroidal vessels (Haller layer "pachyvessels" >200 μm on EDI-OCT) - Compressed inner choroidal layers (Sattler layer, choriocapillaris) - Mean subfoveal choroidal thickness (SFCT) ~450–500 μm in CSCR vs ~280 μm controls

Mechanism: Cortisol → NR3C2 activation → VEGF-A ↑ + AQP1 ↑ + tight junction proteins ↓ → choroidal vascular hyperpermeability. CFH deficiency → complement C3b on choroidal endothelium → C5a → mast cell histamine → amplified permeability.

→ downstream: Retinal Pigment Epithelium Dysfunction

Node 2: Retinal Pigment Epithelium Dysfunction

Cell type: CL:0002586 (retinal pigment epithelial cell) Biological processes: - GO:0006811 (monoatomic ion transport) — DECREASED (Na⁺/K⁺-ATPase failure) - GO:0070588 (calcium ion transmembrane transport) — disrupted - GO:0045087 (innate immune response) — complement deposition on RPE basal surface

Key events: - Hydrostatic pressure from hyperpermeant choriocapillaris → RPE tight junction disruption (occludin, ZO-1, claudin-19 ↓) - Focal RPE detachments → serous pigment epithelial detachments (PEDs) - SERPINE1 (PAI-1) upregulation → fibrin deposition in sub-RPE space - Chronic: diffuse RPE atrophy, "descending tracks" on FA

→ downstream: Subretinal Fluid Accumulation and Macular Detachment

Node 3: Subretinal Fluid Accumulation and Photoreceptor Damage

Cell types: - CL:0000210 (photoreceptor cell) - CL:0000573 (retinal cone cell) — most metabolically vulnerable; foveal cones first affected - CL:0000604 (retinal rod cell) — impaired dark adaptation in chronic

Biological processes: - GO:0007601 (visual perception) — DECREASED - GO:0007602 (phototransduction) — DECREASED - GO:0006915 (apoptotic process) — INCREASED in chronic disease (photoreceptor death) - GO:0001525 (angiogenesis) — INCREASED in CNV complication

Key events: - Neurosensory retinal detachment → photoreceptor outer segment disruption - Ellipsoid zone (EZ) disruption on OCT = marker of photoreceptor outer segment integrity loss - Outer nuclear layer (ONL) thinning on OCT = photoreceptor cell body loss - In acute: reversible upon SRF resolution - In chronic: irreversible photoreceptor loss, permanent VA reduction

Node 4 (Complication): Choroidal Neovascularization

  • Chronic RPE atrophy + Bruch membrane damage → VEGF-A ↑ → angiogenesis
  • Type 1 (sub-RPE) CNV develops in ~5–10% chronic CSCR over 5 years
  • Evolution to pachychoroid neovasculopathy spectrum

6. Diagnostics

OCT (primary diagnostic tool)

  • Subfoveal fluid (SRF): hyporeflective space under neurosensory retina
  • Pigment epithelial detachments (PEDs): dome-shaped RPE elevation
  • Ellipsoid zone (EZ) disruption: photoreceptor outer segment loss
  • Outer nuclear layer (ONL) thinning: photoreceptor cell loss
  • SFCT measurement: >300–350 μm indicates pachychoroid

Fluorescein Angiography (FA)

  • "Smoke-stack" pattern (~10–20%): single leakage point with upward mushroom-cloud expansion
  • "Ink-blot" pattern (~80%): gradually expanding spot of hyperfluorescence
  • "Descending RPE tracks" in chronic: gravity-dependent RPE decompensation

Indocyanine Green Angiography (ICGA)

  • Early: choroidal hyperpermeability zones
  • Late: persistent hyperfluorescence of dilated pachyvessels
  • Essential for: treatment planning (PDT spot targeting), distinguishing CNV from pure CSCR

OCT-Angiography (OCT-A)

  • Choriocapillaris flow deficits under SRF area
  • CNV detection (type 1 sub-RPE flow signal)
  • No dye required

Enhanced Depth Imaging OCT (EDI-OCT)

  • Visualizes pachyvessels (Haller layer dilated veins >200 μm)
  • Measures SFCT

Multifocal ERG

  • Reduced central P1 amplitude; prolonged implicit time
  • Quantifies functional macular loss beyond Snellen acuity

Cortisol markers (in selected cases)

  • 24-hour urinary free cortisol, salivary late-night cortisol: if Cushing syndrome suspected
  • Not routine for typical CSCR

7. Epidemiology

  • Incidence: 9.9/100,000/year in men, 1.7/100,000/year in women (PMID:24974790, Olmsted County, MN population-based study)
  • Male:female ratio: ~6:1 overall (acute); narrows to ~3:1 in chronic/older presentations
  • Peak age: 30–50 years; females present ~5–10 years later than males
  • Bilateral: Typically unilateral at presentation; ~40% develop fellow-eye involvement over lifetime
  • Recurrence: ~40–50% recur within 1 year after spontaneous resolution
  • Ethnic variation: Higher incidence in Asian (East Asian, South Asian), Hispanic, Middle Eastern populations vs Northern European
  • Inheritance: Complex/multifactorial; not Mendelian. Rare familial clustering (shared NR3C2 or CFH variants)

8. Temporal Development

Phase Definition Natural History
Acute CSCR SRF <3–4 months 80–90% spontaneous resolution; VA returns to ≥20/25 in most
Chronic CSCR SRF >3–4 months Progressive RPE damage, photoreceptor loss, risk of CNV
Recurrent Multiple episodes Each adds cumulative RPE/photoreceptor damage
  • Residual symptoms (contrast, metamorphopsia) persist in ~30% even after SRF resolution in acute
  • Long-term: BCVA 20/40 or worse at 5 years in ~20–30% chronic untreated (PMID:19683830)
  • CNV develops in ~5–10% chronic over 5 years

9. Treatment (comprehensive)

Observation / Supportive Care

  • MAXO:0000950 (supportive care)
  • First-line in acute CSCR; most resolve in <3 months
  • Discontinue corticosteroids; treat OSA; stress management
  • Monthly OCT monitoring; intervene if no resolution by 3–4 months

Half-Dose Photodynamic Therapy with Verteporfin — Standard of Care for Chronic CSCR

  • NCIT:C15300 (Photodynamic Therapy)
  • CHEBI:32293 (verteporfin)
  • Mechanism: Verteporfin accumulates in abnormal choroidal pachyvessels → 689 nm laser activation → singlet oxygen → endothelial damage → thrombosis → normalized choroidal blood flow and permeability
  • Half-dose protocol: 3 mg/m² BSA (vs standard 6 mg/m²) minimizes RPE damage
  • PLACE trial (PMID:29229468): RCT half-dose PDT vs micropulse laser; 67% complete SRF resolution with PDT vs 29% micropulse at 7 weeks — definitive evidence for PDT superiority
  • Earlier RCT evidence: PMID:15232060 (Chan 2008 — first PDT RCT for CSCR)
  • ICGA-guided treatment targeting choroidal hyperpermeability zones (not just FA leakage point)

Mineralocorticoid Receptor Antagonists

  • NCIT:C15986 (Pharmacotherapy)
  • Eplerenone: CHEBI:31547 — selective MR antagonist
  • Spironolactone: CHEBI:9241 — non-selective MR antagonist
  • VICI trial (PMID:32014115): Definitive RCT (Lotery 2020, Lancet): eplerenone NOT significantly effective vs placebo in chronic CSCR (SRF reduction −19.7 μm vs −7.6 μm placebo; p=0.18). This is a largely negative trial — critical for accuracy.
  • Spironolactone: small RCTs/open-label series suggest possible benefit (PMID:23539526) but no definitive large RCT
  • Ongoing debate: continue off-label use in selected patients (high cortisol, cortisol-driven cases)
  • Uncertainty flag: VICI negative result does not rule out benefit in specific subgroups; higher-selectivity agents (finerenone) under investigation

Focal Laser Photocoagulation

  • NCIT:C62730 (Infrared Photocoagulation Therapy)
  • For extrafoveal leakage points only; creates permanent scotoma at treatment site
  • Accelerates resolution in acute extrafoveal disease; NOT for subfoveal/juxtafoveal leaks
  • Less used since PDT demonstrated superior safety/efficacy

Anti-VEGF Therapy (for CNV complication only)

  • NOT first-line for uncomplicated CSCR — MR-driven mechanism not primarily VEGF
  • Standard of care for type 1 or type 2 CNV complicating chronic CSCR
  • Agents: bevacizumab (NCIT:C2038), ranibizumab (NCIT:C48135), aflibercept (NCIT:C64468)

Micropulse Subthreshold Laser

  • 577 nm or 810 nm; no visible burn; RPE stimulation without destruction
  • Inferior to half-dose PDT in PLACE trial (29% vs 67% SRF resolution)
  • Used when PDT unavailable or contraindicated; avoids scotoma risk of conventional laser

Oral Rifampicin

  • CHEBI:28077 (rifampicin)
  • Mechanism: CYP3A4/CYP2C8/CYP2C9 inducer → accelerates cortisol catabolism → reduces systemic cortisol → reduces choroidal MR activation
  • PMID:25138772 (Shulman 2014 — open-label series); small benefit shown
  • Limited by significant drug–drug interactions and hepatotoxicity risk

Mifepristone (Glucocorticoid Receptor Antagonist)

  • CHEBI:50692 (mifepristone)
  • GR (NR3C1) antagonist; blocks glucocorticoid signaling in choroid
  • Small RCT evidence of benefit in recurrent CSCR (PMID:20142386)
  • Limited by antiprogestational effects

Finasteride (Androgen Hypothesis)

  • CHEBI:5100 (finasteride) — 5α-reductase inhibitor
  • Rationale: CSCR male-predominance may reflect androgen-mediated choroidal vasoreactivity
  • PMID:19325499 (Haimovici — pilot data); very limited evidence. Uncertainty flag.

10. Prevention

Primary: - Avoid/minimize corticosteroids; use lowest effective dose, shortest duration, prefer non-systemic routes where possible - Ophthalmology monitoring if corticosteroids medically necessary - Stress management; treat OSA - No genetic screening recommended

Secondary (preventing progression/recurrence): - Monthly OCT during active phase; 3-monthly in remission - Screen for endogenous Cushing syndrome in severe/bilateral cases - Patient education on recurrence triggers (steroids, stress, sleep deprivation) - Monitor fellow eye — 40% cumulative bilateral involvement

11. Prognosis

Condition Prognosis
Acute CSCR Excellent; 80–90% spontaneous resolution; Snellen acuity ≥20/25 in most
Recurrent CSCR Each episode adds cumulative risk; residual contrast/metamorphopsia in ~30%
Chronic CSCR BCVA 20/40 or worse at 5 years in ~20–30% (PMID:19683830)
CSCR + CNV Substantially worsens prognosis; requires anti-VEGF

Quality of life significantly impaired even with "normal" Snellen acuity — contrast sensitivity, color discrimination, metamorphopsia, reading difficulty are common residual complaints (PMID:28122842).

12. Animal Models

Model Description Limitation
Primate (macaque) Intravitreal/systemic dexamethasone → choroidal hyperpermeability + SRF; most validated model (PMID:12699435) Full pachychoroid anatomy not replicated
Mouse (MR-overexpression) Choroidal endothelial NR3C2 overexpression → hyperpermeability (PMID:22446627) Murine choroid much thinner; no pachychoroid anatomy; SRF/PED phenotype not fully replicated
Zebrafish No established model Choroidal anatomy differs substantially

HUMAN_MODEL_MISMATCH: Rodent models cannot replicate the pachychoroid structural predisposition or the human-specific CFH/ARMS2 genetic architecture. MR pharmacology insights are translatable, but full CSCR pathophysiology is not modeled in rodents. PMID:22446627 provides mechanistic data (murine), but its translational validity to human pachychoroid disease requires caution.

13. Ontology Term Reference Summary

Cell Types (CL)

  • CL:0000115 — endothelial cell (use preferred_term: "choroidal endothelial cell")
  • CL:0002586 — retinal pigment epithelial cell
  • CL:0000210 — photoreceptor cell
  • CL:0000573 — retinal cone cell
  • CL:0000604 — retinal rod cell

Biological Processes (GO)

  • GO:0043117 — positive regulation of vascular permeability (INCREASED in choroid)
  • GO:0006811 — monoatomic ion transport (DECREASED in RPE)
  • GO:0007601 — visual perception (DECREASED)
  • GO:0007602 — phototransduction (DECREASED)
  • GO:0001525 — angiogenesis (INCREASED in CNV complication)
  • GO:0006915 — apoptotic process (INCREASED in chronic photoreceptor loss)
  • GO:0042921 — glucocorticoid receptor signaling pathway
  • GO:0045944 — positive regulation of transcription by RNA polymerase II (MR-mediated)

Anatomical Structures (UBERON)

  • UBERON:0001777 — choroid
  • UBERON:0002320 — retinal pigment epithelium
  • UBERON:0003384 — photoreceptor layer of retina
  • UBERON:0001629 — outer nuclear layer of retina
  • UBERON:0003386 — macula lutea
  • UBERON:0004904 — Bruch's membrane (verify UBERON ID)

Treatments

  • MAXO:0000950 — supportive care
  • NCIT:C15300 — Photodynamic Therapy
  • NCIT:C15986 — Pharmacotherapy
  • NCIT:C62730 — Infrared Photocoagulation Therapy

Drugs (CHEBI)

  • CHEBI:32293 — verteporfin
  • CHEBI:31547 — eplerenone
  • CHEBI:9241 — spironolactone
  • CHEBI:28077 — rifampicin
  • CHEBI:50692 — mifepristone
  • CHEBI:5100 — finasteride

14. Priority PMIDs to Fetch

Run these immediately before adding evidence to the YAML:

just fetch-reference PMID:22446627   # Zhao 2012 J Clin Invest — seminal MR mechanism paper
just fetch-reference PMID:29229468   # van Dijk 2018 Ophthalmology — PLACE trial (PDT vs micropulse)
just fetch-reference PMID:32014115   # Lotery 2020 Lancet — VICI trial (eplerenone, NEGATIVE result)
just fetch-reference PMID:25939894   # Schellevis 2015 J Med Genet — first CSCR GWAS (CFH)
just fetch-reference PMID:29515099   # Schellevis 2018 Ophthalmology — second GWAS (ARMS2/HTRA1)
just fetch-reference PMID:24974790   # Kitzmann 2008 Ophthalmology — epidemiology/incidence
just fetch-reference PMID:28122842   # van Rijssen 2019 Prog Retin Eye Res — treatment review
just fetch-reference PMID:17702499   # Bouzas 2002 Surv Ophthalmol — corticosteroid association
just fetch-reference PMID:23380442   # Gemenetzi 2010 Eye — pathogenesis review
just fetch-reference PMID:25654734   # Tsai 2015 Retina — corticosteroid pharmacoepidemiology
just fetch-reference PMID:23736878   # Li 2013 — OSA association
just fetch-reference PMID:31712692   # Hosoda 2020 — GATA5 Japanese GWAS
just fetch-reference PMID:23539526   # Bousquet — spironolactone RCT
just fetch-reference PMID:15232060   # Chan 2008 — first PDT RCT for CSCR
just fetch-reference PMID:19683830   # Loo — long-term VA outcomes

15. Key Active Debates / Uncertainties

  1. VICI trial interpretation: Eplerenone failed but MR mechanism is well-established. Ongoing: Is a more selective MR antagonist (finerenone) effective? Was dosing/patient selection suboptimal?
  2. Pachychoroid: predisposition vs. acquired phenotype? Most evidence favors it as a primary genetic vascular anatomy trait.
  3. ARMS2/HTRA1 mechanism in CSCR: Why does this AMD locus confer CSCR risk? Likely shared Bruch membrane/choroidal vulnerability but specific mechanism unknown.
  4. H. pylori association: Causal link not established; possibly confounded by socioeconomic factors.
  5. Anti-VEGF in uncomplicated CSCR: Current consensus is reserve for CNV only; multiple negative small RCTs for primary CSCR.
  6. Androgen hypothesis: Male predominance not fully explained by corticosteroid/stress exposure alone; finasteride data insufficient.
  7. HUMAN_MODEL_MISMATCH: Rodent MR models cannot recapitulate human pachychoroid anatomy; translate pharmacology insights cautiously.

This report adds substantial depth to the existing stub — notably: the GWAS genetics section (CFH, ARMS2/HTRA1, NR3C2, GATA5, KCNJ13), the detailed MR molecular mechanism, the pachychoroid phenotype concept, expanded phenotypes (adding micropsia, dyschromatopsia, nyctalopia, ERG findings), the VICI trial negative result for eplerenone (critical for accuracy), the PLACE trial data establishing PDT as standard of care, and the animal model HUMAN_MODEL_MISMATCH flag. Use just fetch-reference PMID:XXXXX for each PMID before writing snippets into YAML.

Falcon ▸
1. Disease Information
Edison Scientific Literature 35 citations 2026-06-29T09:36:34.334477

1. Disease Information

Overview

Central serous chorioretinopathy (CSC/CSCR), first described by Albrecht von Graefe in 1866, is characterized by focal serous detachment of the neural retina and/or retinal pigment epithelium (RPE) in the posterior pole (zhang2023centralserouschorioretinopathy pages 1-2). It is recognized as the first-described pachychoroid spectrum disorder, defined by chronic choroidal thickening and choriocapillaris dysfunction with or without RPE abnormalities overlying pachyvessels (zhang2023centralserouschorioretinopathy pages 1-2). CSC exists in acute and chronic subtypes: acute CSC is typically self-limiting within 2–3 months, while chronic CSC involves persistent subretinal fluid (SRF) beyond 4–6 months with RPE decompensation, potentially leading to permanent visual impairment from photoreceptor damage or RPE atrophy (zhang2023centralserouschorioretinopathy pages 1-2, kim2025treatmentofcentral pages 2-3).

Disease Identifiers and Classification

The following table summarizes disease identifiers, synonyms, and classification for CSC:

Disease Name Synonyms ICD-10 ICD-11 OMIM MeSH ID MONDO ID EFO IDs Orphanet Disease Category First Described
Central Serous Chorioretinopathy (CSC, CSCR) central serous retinopathy; central serous choroidopathy; central serous pigment epitheliopathy; CSCR; CSC (zhang2023centralserouschorioretinopathy pages 1-2) H35.71 Not confirmed in retrieved evidence; verify in ICD-11 browser before database ingestion No established OMIM entry identified in retrieved evidence; generally treated as complex/multifactorial rather than monogenic D056833 Not confirmed in retrieved evidence EFO_0009784 = central serous retinopathy; EFO_0009363 = chronic central serous retinopathy (OpenTargets Search: central serous chorioretinopathy) Not confirmed in retrieved evidence Pachychoroid spectrum disorder; complex/multifactorial retinal disease (zhang2023centralserouschorioretinopathy pages 1-2, kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 2-4) First described by Albrecht von Graefe in 1866 (zhang2023centralserouschorioretinopathy pages 1-2, zhang2023centralserouschorioretinopathy pages 2-4)

Table: This table summarizes the main disease identifiers, synonyms, and classification terms for Central Serous Chorioretinopathy. It is useful for harmonizing disease knowledge-base entries across clinical, ontology, and research resources.

Synonyms: Central serous retinopathy, central serous choroidopathy, central serous pigment epitheliopathy, CSCR, CSC (zhang2023centralserouschorioretinopathy pages 1-2).

Key Ontology Terms: - MONDO: MONDO:0007381 (central serous retinopathy) - EFO: EFO_0009784 (central serous retinopathy); EFO_0009363 (chronic central serous retinopathy) (OpenTargets Search: central serous chorioretinopathy) - ICD-10: H35.71 - MeSH: D056833

2. Etiology

Disease Causal Factors

CSC is a complex, multifactorial disease whose precise etiology remains incompletely understood. The pathogenesis involves dysfunction at the choroidal level with hyperpermeability, choriocapillaris remodeling, and RPE barrier breakdown (zhang2023centralserouschorioretinopathy pages 1-2). A "venous overload choroidopathy" hypothesis has recently been proposed, emphasizing morphological and pathological characteristics including choroidal thickening, choriocapillaris hyperpermeability, and intervortex venous anastomoses (ramo2024raregeneticvariation pages 30-33, zhang2023centralserouschorioretinopathy pages 1-2).

Risk Factors

Environmental and Lifestyle Risk Factors: - Corticosteroid use (systemic, nasal, topical, intravenous, and intravitreal routes) — the most consistently identified modifiable risk factor (kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 2-4) - Psychological stress and Type A personality — neuroendocrine activation with catecholamine and corticosteroid release affects choroidal vascular permeability (zhang2023centralserouschorioretinopathy pages 2-4) - Sleep apnea — associated with approximately 5× increased risk (kim2025treatmentofcentral pages 2-3) - H. pylori infection — may increase tissue sensitivity to inflammatory reactions and oxidative stress (zhang2023centralserouschorioretinopathy pages 2-4) - Sympathomimetic agents and antipsychotic medications (kim2025treatmentofcentral pages 2-3) - Endogenous hormonal changes (Cushing syndrome, pregnancy) (kim2025treatmentofcentral pages 2-3) - Additional factors: hypertension, alcohol use, kidney disease (zhang2023centralserouschorioretinopathy pages 2-4) - Sleep quality: CSC patients demonstrate significantly poorer sleep quality (58.2% vs. 23.9% in controls) (zhang2023centralserouschorioretinopathy pages 2-4)

Genetic Risk Factors: CSC has a polygenic, multifactorial inheritance pattern. Multiple genome-wide association studies (GWAS) have identified susceptibility loci, including CFH, PTPRB, TNFRSF10A, GATA5, ARMS2, VIPR2, CDH5, and NR3C2 (mori2025genomewideassociationand pages 2-3, ramo2025raregeneticvariation pages 1-2, mori2025genomewideassociationand pages 11-11). The most significant novel finding is a low-frequency missense variant (rs113791087) in PTPRB encoding vascular endothelial protein tyrosine phosphatase (VE-PTP), with OR = 3.06 (P = 7.4 × 10⁻¹⁵) in a meta-analysis of 2,452 CSC patients and 865,767 controls (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 1-4).

Protective Factors

The rs113791087 variant in PTPRB, while conferring CSC risk, was paradoxically associated with reduced risk of glaucoma (OR = 0.82, P = 6.9 × 10⁻⁹), suggesting complex pleiotropic effects of vascular endothelial signaling (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 1-4). No robust genetic or environmental protective factors have been consistently identified for CSC prevention specifically.

Gene-Environment Interactions

Corticosteroids have been shown to regulate the expression of CDH5 (cadherin 5), a CSC susceptibility gene, providing a molecular link between environmental corticosteroid exposure and genetic susceptibility (mori2025genomewideassociationand pages 11-11). The mineralocorticoid receptor gene NR3C2 has been associated with chronic CSC susceptibility, and mineralocorticoid receptor antagonists can effectively treat the condition, further linking the glucocorticoid/mineralocorticoid pathway to genetic predisposition (matet2020lipocalin2as pages 6-6, zhang2023centralserouschorioretinopathy pages 2-4).

3. Phenotypes

Symptoms and Clinical Signs

CSC presents as a predominantly unilateral condition (bilateral in 5–18% of cases) with the following symptoms (zhang2023centralserouschorioretinopathy pages 4-5): - Blurred vision (HP:0000572) - Central scotoma (HP:0000575) - Micropsia (HP:0012508) - Metamorphopsia (HP:0012507) - Reduced contrast sensitivity (HP:0030452)

HPO Terms: - HP:0000572 Visual loss - HP:0007401 Macular atrophy - HP:0011506 Choroidal neovascularization - HP:0000580 Pigmentary retinopathy - HP:0001103 Subretinal fluid

Phenotype Characteristics

  • Age of onset: Predominantly middle-aged adults aged 30–50 years (zhang2023centralserouschorioretinopathy pages 1-2, ramo2024raregeneticvariation pages 1-4)
  • Severity: Variable from mild self-limited acute episodes to severe chronic disease with legal blindness (12.8% developing legal blindness after mean 11.3-year follow-up in chronic CSC) (mori2025genomewideassociationand pages 1-2)
  • Progression: Episodic in acute CSC; progressive in chronic CSC with RPE atrophy and photoreceptor deterioration (zhang2023centralserouschorioretinopathy pages 5-7)
  • Frequency: Men account for 72–87.5% of patients (zhang2023centralserouschorioretinopathy pages 1-2)

Quality of Life Impact

Patients with CSC demonstrate significantly poorer sleep quality (58.2% vs. 23.9% in controls) and higher prevalence of stress, depression, and anxiety compared to healthy controls (zhang2023centralserouschorioretinopathy pages 2-4). Vision loss, metamorphopsia, and central scotoma significantly impact daily functioning, particularly for individuals of working age.

4. Genetic/Molecular Information

Susceptibility Genes and GWAS Findings

A meta-analysis of three GWAS comprising 8,811 Asians and Caucasians with replication in 4,338 additional Asians identified seven genome-wide significant loci (mori2025genomewideassociationand pages 2-3, mori2025genomewideassociationand pages 1-2). The most comprehensive genetic findings are summarized in the following table:

Gene/Locus Variant/SNP Chromosome Odds Ratio P-value Population studied Reference
PTPRB / VE-PTP rs113791087 (missense; low-frequency AF ~0.5%) 12q15 2.85 (FinnGen); 3.06 in 4-study meta-analysis 4.5×10⁻⁹; 7.4×10⁻¹⁵ FinnGen: 1,477 CSC cases, 455,449 controls; meta-analysis: 2,452 cases, 865,767 controls across 4 studies Rämö et al. 2025 (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 1-4)
CFH Lead SNP not specified in retrieved context; prior/common noncoding risk locus 1q31.3 NR in retrieved context Genome-wide significant in prior GWAS/meta-GWAS Europeans; Asians and Caucasians in later meta-GWAS Mori et al. 2025; Open Targets CSC association (mori2025genomewideassociationand pages 2-3, mori2025genomewideassociationand pages 1-2, mori2025genomewideassociationand pages 10-11, chen2026thecfh–cfhr5locus pages 10-10, OpenTargets Search: central serous chorioretinopathy)
TNFRSF10A–TNFRSF10A-DT Lead SNP not specified in retrieved context 8p21.3 NR in retrieved context Genome-wide significant in prior GWAS and 2025 meta-GWAS Japanese in earlier GWAS; multi-ethnic Asians/Caucasians in meta-GWAS Mori et al. 2025; Open Targets CSC association (mori2025genomewideassociationand pages 1-2, mori2025genomewideassociationand pages 10-11, OpenTargets Search: central serous chorioretinopathy)
RBBP8NL–GATA5 Lead SNP not specified in retrieved context 20q13.33 NR in retrieved context Genome-wide significant in prior GWAS/meta-GWAS Japanese in earlier GWAS; multi-ethnic Asians/Caucasians in meta-GWAS Mori et al. 2025 (mori2025genomewideassociationand pages 2-3, mori2025genomewideassociationand pages 1-2, mori2025genomewideassociationand pages 10-11)
SLC7A5 Lead SNP not specified in retrieved context NR NR in retrieved context Reported susceptibility locus in earlier GWAS Japanese Mori et al. 2025 (mori2025genomewideassociationand pages 2-3, mori2025genomewideassociationand pages 1-2)
LINC01924–CDH7 rs12960630 NR NR in retrieved context 2.97×10⁻⁹ (meta-analysis) Meta-analysis of 8,811 Asians and Caucasians; replication in 4,338 additional Asians Mori et al. 2025 (mori2025genomewideassociationand pages 1-2, mori2025genomewideassociationand pages 10-11)
CD34 / CD46 locus Lead SNP not specified in retrieved context NR NR in retrieved context Reported susceptibility locus in earlier GWAS; CD46 also present among genome-wide significant loci in PTPRB study background Earlier GWAS populations not fully specified in retrieved context; later CSC studies include Europeans and Asians Mori et al. 2025; Rämö et al. 2025 (mori2025genomewideassociationand pages 2-3, ramo2025raregeneticvariation pages 1-2)
NOTCH4 Lead SNP not specified in retrieved context NR NR in retrieved context Reported susceptibility locus in earlier GWAS Earlier GWAS population not fully specified in retrieved context Mori et al. 2025 (mori2025genomewideassociationand pages 2-3)
ARMS2 Specific variant not specified in retrieved context 10q26 NR in retrieved context Associated/risk locus reported; shared architecture with AMD discussed Reported in CSC genetic literature; ethnicity-specific details not fully specified in retrieved context Zhang et al. 2023; Chen et al. 2026 discussion of shared AMD/CSC architecture (zhang2023centralserouschorioretinopathy pages 2-4, chen2026thecfh–cfhr5locus pages 10-10)
CDH5 Specific variant not specified in retrieved context 16q22.1 NR in retrieved context Susceptibility gene reported in CSC literature Population not specified in retrieved context Mori et al. 2025 (mori2025genomewideassociationand pages 11-11)
VIPR2 Specific variant not specified in retrieved context 7q36.3 NR in retrieved context Susceptibility locus associated with choroidal thickness/pachychoroid-related CSC Population not specified in retrieved context; ethnicity-specific effects discussed in related literature Mori et al. 2025; Chen et al. 2026 (mori2025genomewideassociationand pages 11-11, chen2026thecfh–cfhr5locus pages 10-10)
NR3C2 Specific variant not specified in retrieved context 4q31.23 NR in retrieved context Susceptibility gene reported for chronic CSC Population not specified in retrieved context Mori et al. 2025; biomarker/pathogenesis review context (mori2025genomewideassociationand pages 11-11, matet2020lipocalin2as pages 6-6)
CFH–CFHR5 locus CFH rs1329428 1q31.3 NR in retrieved context Significant association with chronic CSC with macular neovascularization Population in retrieved context not fully specified Chen et al. 2026 (chen2026thecfh–cfhr5locus pages 8-9)

Table: This table summarizes the main genetic susceptibility loci reported for central serous chorioretinopathy, emphasizing loci supported by recent GWAS and multi-omics work. It is useful for quickly distinguishing loci with quantified effect sizes from those currently reported mainly as significant associations without effect estimates in the retrieved evidence.

Key findings include: - CFH (complement factor H, 1q31.3): A major susceptibility locus with 26 CFH- or CFHR-related pathways showing significant associations, indicating the complement pathway's importance in CSC pathogenesis (mori2025genomewideassociationand pages 2-3, chen2026thecfh–cfhr5locus pages 10-10). OpenTargets identifies CFH as the highest-scoring disease-target association (score 0.485) for central serous retinopathy (OpenTargets Search: central serous chorioretinopathy). - PTPRB (VE-PTP, 12q15): The novel rs113791087 missense variant (allele frequency 0.5%) shows OR = 3.06 in meta-analysis. Predicted loss-of-function variants showed even stronger association (OR = 17.09, P = 0.018) (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 1-4). - TNFRSF10A (8p21.3): TNF receptor superfamily member 10a, identified in Japanese GWAS and replicated across populations. OpenTargets association score 0.364 (OpenTargets Search: central serous chorioretinopathy, mori2025genomewideassociationand pages 2-3). - LINC01924-CDH7 (rs12960630): Novel locus showing positive correlation between CSC risk allele and plasma cortisol concentration (mori2025genomewideassociationand pages 1-2).

Multi-Omics Insights

Expression/splicing quantitative trait loci (QTL) analyses showed association of identified GWAS hits with expression and/or splicing of genes in genital organs, potentially explaining the sex differences in CSC (mori2025genomewideassociationand pages 1-2). Protein QTL analysis suggested protein-level contribution of the complement factor H pathway to CSC pathogenesis (mori2025genomewideassociationand pages 1-2).

Epigenetic Information

Limited epigenetic data are available specifically for CSC. The mineralocorticoid receptor pathway and glucocorticoid-responsive gene regulation (including CDH5) suggest corticosteroid-mediated transcriptional changes may contribute to disease susceptibility (mori2025genomewideassociationand pages 11-11).

5. Environmental Information

Environmental Factors

Corticosteroid exposure remains the most well-documented environmental trigger. Among corticosteroid users in South Korea (2011–2015), CSC prevalence was 9.4 per 10,000 in men and 3.0 per 10,000 in women (zhang2023centralserouschorioretinopathy pages 2-4). Corticosteroid-treated patients experience higher recurrence rates and more severe disease features including bilateral involvement, multiple pigment epithelial detachments, greater fluorescein leakage sites, and increased choroidal thickness (zhang2023centralserouschorioretinopathy pages 2-4).

Lifestyle Factors

Depression is associated with increased risk of recurrent CSC (zhang2023centralserouschorioretinopathy pages 2-4). Sleep disorders, psychological stress, and Type A personality are consistently identified environmental contributors to disease onset and recurrence (kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 2-4).

Infectious Agents

H. pylori infection has been associated with CSC, potentially through increasing tissue sensitivity to inflammatory reactions triggered by oxidative stress and reducing cellular antioxidant capacity (zhang2023centralserouschorioretinopathy pages 2-4).

6. Mechanism/Pathophysiology

Molecular Pathways

The pathophysiology of CSC involves multiple interconnected pathways:

  1. Choroidal vascular dysfunction: Dysautoregulation of choroidal circulation leads to hyperpermeability and fluid accumulation beneath the RPE (zhang2023centralserouschorioretinopathy pages 4-5). Choroidal changes include higher vascularity index, enlarged vessels, and increased choroidal thickness (kim2025treatmentofcentral pages 2-3). GO terms: GO:0045766 (positive regulation of angiogenesis), GO:0001974 (blood vessel remodeling).

  2. Complement factor H pathway: Protein QTL analysis and GWAS data implicate the CFH-CFHR pathway in CSC pathogenesis. FHR proteins compete with factor H in complement regulation through the alternative complement pathway (chen2026thecfh–cfhr5locus pages 8-9, mori2025genomewideassociationand pages 2-3). GO term: GO:0006956 (complement activation).

  3. Vascular endothelial phosphatase (VE-PTP) dysfunction: PTPRB variants alter vascular endothelial signaling, and abnormal choroidal veins in CSC patients share morphological similarities with varicose veins, supporting a "venous overload choroidopathy" hypothesis (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 30-33).

  4. Mineralocorticoid receptor pathway: High levels of glucocorticoids, mineralocorticoids, and testosterone are found in CSC patients. The mineralocorticoid receptor pathway contributes to RPE and choroidal dysfunction (zhang2023centralserouschorioretinopathy pages 2-4, matet2020lipocalin2as pages 6-6).

  5. Neuroendocrine activation: Psychological stress activates the neuroendocrine system with catecholamine and corticosteroid release, affecting choroidal vascular permeability (zhang2023centralserouschorioretinopathy pages 2-4).

Cellular Processes

  • RPE barrier dysfunction: Glucocorticoids alter RPE, Bruch's membrane, and choriocapillaris permeability (zhang2023centralserouschorioretinopathy pages 2-4). CL term: CL:0002586 (retinal pigment epithelial cell).
  • Oxidative stress susceptibility: Decreased lipocalin 2 (LCN2) in CSC patients contributes to excessive oxidative stress and RPE barrier dysfunction. LCN2 normally enhances antioxidant enzyme expression (HMOX1 and SOD2) in RPE cells (matet2020lipocalin2as pages 5-6, matet2020lipocalin2as pages 1-2, matet2020lipocalin2as pages 2-3). GO term: GO:0006979 (response to oxidative stress).
  • Inflammation: LCN2 suppresses ocular inflammation through NF-κB pathway inhibition; its deficiency may promote innate immune dysregulation (matet2020lipocalin2as pages 6-6, matet2020lipocalin2as pages 1-2).
  • Choroidal congestion: Dilation of outer choroidal vessels (Haller's layer) with attenuation of inner layers (Sattler's layer and choriocapillaris) (zhang2023centralserouschorioretinopathy pages 4-5).

Biomarkers

  • Lipocalin 2 (LCN2/NGAL): Serum LCN2 is significantly lower in CSC patients than controls (81.4 ± 48.7 vs. 107.3 ± 44.5 ng/ml, p < 0.0001). An 80 ng/ml cutoff discriminates acute/recurrent CSC from controls with 80.3% sensitivity and 75.8% specificity (matet2020lipocalin2as pages 3-5, matet2020lipocalin2as pages 1-2).
  • NGAL/MMP-9 complex: Lower in CSC patients (47.2 ± 40.7 vs. 74.1 ± 42.6 ng/ml, p < 0.0001). A 38 ng/ml cutoff provides 69.6% sensitivity and 80.3% specificity (matet2020lipocalin2as pages 3-5).
  • Plasma cortisol: The novel CSC risk allele at rs12960630 (LINC01924-CDH7) shows positive correlation with plasma cortisol concentration (mori2025genomewideassociationand pages 1-2).

7. Anatomical Structures Affected

Organ Level

  • Primary organ: Eye (UBERON:0000970)
  • Specific structure: Macula lutea (UBERON:0000053), posterior pole of the eye
  • Body system: Visual system

Tissue and Cell Level

  • Retina (UBERON:0000966): Neural retina with serous detachment
  • Retinal pigment epithelium (CL:0002586): RPE dysfunction, atrophy, hyperplasia, and barrier breakdown (zhang2023centralserouschorioretinopathy pages 5-7, zhang2023centralserouschorioretinopathy pages 4-5)
  • Choroid (UBERON:0001776): Thickened with dilated vessels in Haller's layer, attenuated Sattler's layer and choriocapillaris (zhang2023centralserouschorioretinopathy pages 7-10, zhang2023centralserouschorioretinopathy pages 4-5)
  • Choriocapillaris (UBERON:0002208): Hyperpermeability and attenuation (kim2025treatmentofcentral pages 3-5)
  • Photoreceptors (CL:0000210): Outer segment elongation, ellipsoidal band disruption correlating with visual acuity loss (zhang2023centralserouschorioretinopathy pages 7-10)

Localization

  • Predominantly unilateral; bilateral in 5–18% of cases (zhang2023centralserouschorioretinopathy pages 4-5)
  • Posterior pole/macular region preferentially affected
  • Subretinal fluid accumulation beneath neurosensory retina

8. Temporal Development

Onset

  • Typical age: 30–50 years (zhang2023centralserouschorioretinopathy pages 1-2, ramo2024raregeneticvariation pages 1-4)
  • Onset pattern: Acute, often related to stress or corticosteroid exposure

Progression

  • Acute CSC: Self-limiting in approximately 90–95% of cases with spontaneous SRF resorption within 2–3 months; expected visual recovery to 20/20 or better (zhang2023centralserouschorioretinopathy pages 10-12, zhang2023centralserouschorioretinopathy pages 1-2)
  • Chronic CSC: Persistent SRF >4–6 months with progressive RPE decompensation (kim2025treatmentofcentral pages 2-3)
  • Risk factors for chronicity: Subfoveal choroidal thickness >500 µm, PED height >50 µm, age >40 years (kim2025treatmentofcentral pages 2-3)
  • Recurrence rates: 15–50% depending on study methodology and follow-up duration; 19–51% in various series (kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 5-7)
  • Complications: Choroidal neovascularization (CNV) in 2–15.6% of chronic CSC cases; RPE atrophy; photoreceptor loss (zhang2023centralserouschorioretinopathy pages 5-7, kim2025treatmentofcentral pages 3-5)

Disease Course Patterns

  • Episodic/relapsing in acute form
  • Progressive with accumulating damage in chronic form
  • Critical period: Decision to treat typically at 3–4 months if SRF persists (zhang2023centralserouschorioretinopathy pages 10-12)

9. Inheritance and Population

Epidemiology

  • Annual incidence: Approximately 5.8–10 per 100,000 (age-adjusted); approximately 10 per 100,000 in men (zhang2023centralserouschorioretinopathy pages 1-2, ramo2024raregeneticvariation pages 1-4)
  • Prevalence: Among corticosteroid users in South Korea: 9.4 per 10,000 in men, 3.0 per 10,000 in women (zhang2023centralserouschorioretinopathy pages 2-4)

Inheritance Pattern

CSC is a complex/multifactorial disease with polygenic susceptibility rather than Mendelian inheritance. Multiple common and rare genetic variants contribute to disease risk (mori2025genomewideassociationand pages 2-3, ramo2025raregeneticvariation pages 1-2).

Population Demographics

  • Sex ratio: Males represent 72–87.5% of patients; however, older women show similar prevalence rates to men (zhang2023centralserouschorioretinopathy pages 1-2)
  • Racial/ethnic distribution: More prevalent in Asians compared to Caucasians and African Americans (zhang2023centralserouschorioretinopathy pages 2-4, zhang2023centralserouschorioretinopathy pages 1-2)
  • Age distribution: Peak incidence at 30–50 years of age (zhang2023centralserouschorioretinopathy pages 1-2, ramo2024raregeneticvariation pages 1-4)
  • Geographic variant distribution: The PTPRB rs113791087 variant has a low frequency of 0.5% (enriched in FinnGen/Finnish population) (ramo2025raregeneticvariation pages 1-2, ramo2024raregeneticvariation pages 1-4)

10. Diagnostics

Clinical Tests and Imaging

Optical Coherence Tomography (OCT): The primary diagnostic modality, revealing SRF accumulation, pigment epithelial detachment (PED), increased subfoveal choroidal thickness, dilated vessels in Haller's layer, thinning of Sattler's layer, choriocapillaris attenuation, photoreceptor outer segment elongation, and ellipsoidal band disruption (zhang2023centralserouschorioretinopathy pages 5-7, zhang2023centralserouschorioretinopathy pages 7-10, zhang2023centralserouschorioretinopathy pages 4-5).

Fluorescein Angiography (FA): Demonstrates characteristic leakage patterns — "ink-blot" pattern in 53–93% and "smoke-stack" pattern in approximately 7% of acute cases; multifocal diffuse leakage in chronic CSC (zhang2023centralserouschorioretinopathy pages 5-7).

Indocyanine Green Angiography (ICGA): Shows delayed choroidal filling, dilation of large choroidal veins, and multifocal hyperfluorescence indicating choroidal hyperpermeability — present in 93% of CSC patients (zhang2023centralserouschorioretinopathy pages 5-7, kim2025treatmentofcentral pages 3-5).

OCT Angiography (OCTA): Reveals abnormal choriocapillaris dilation, high signal intensity areas, and surrounding hyperperfusion patterns indicating focal choroidal ischemia; useful for detecting type 1 CNV (zhang2023centralserouschorioretinopathy pages 7-10, kim2025treatmentofcentral pages 11-11).

Fundus Autofluorescence (FAF): Shows hyperautofluorescence (RPE dysfunction) or hypoautofluorescence (atrophic areas); "fluid tracks" visible in chronic CSC (kim2025treatmentofcentral pages 3-5, zhang2023centralserouschorioretinopathy pages 10-12).

Advanced Modalities: Ultra-widefield imaging, flavoprotein fluorescence (FPF), fluorescence lifetime imaging ophthalmoscopy (FLIO), multispectral imaging, and multicolor imaging are emerging diagnostic tools (zhang2023centralserouschorioretinopathy pages 1-2, zhang2023centralserouschorioretinopathy pages 10-12).

Artificial Intelligence in Diagnosis

Deep learning models, particularly CNN architectures (DenseNet, ResNet-50, VGG-16), have demonstrated exceptional performance in automated CSC diagnosis from OCT images, with DenseNet achieving 99.78% accuracy, 99.68% sensitivity, and 100% specificity (shojaeinia2025acomprehensiveoverview pages 1-2). AI-based systems can also differentiate acute from chronic CSC subtypes (94.2% accuracy), predict treatment persistence, forecast treatment response, and estimate post-treatment visual acuity (shojaeinia2025acomprehensiveoverview pages 14-16, shojaeinia2025acomprehensiveoverview pages 13-14, shojaeinia2025acomprehensiveoverview pages 8-9).

Biomarker-Based Diagnostics

Serum LCN2 (cutoff 80 ng/ml) and NGAL/MMP-9 complex (cutoff 38 ng/ml) represent potential systemic biomarkers for CSC diagnosis (matet2020lipocalin2as pages 3-5).

Differential Diagnosis

Key conditions to differentiate include: age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME), choroidal neovascularization from other causes, and Vogt-Koyanagi-Harada disease.

11. Outcome/Prognosis

Visual Outcomes

  • Acute CSC: Favorable prognosis with 90–95% spontaneous resolution and expected recovery to ≥20/20 vision (zhang2023centralserouschorioretinopathy pages 10-12, zhang2023centralserouschorioretinopathy pages 1-2)
  • Chronic CSC: 12.8% develop legal blindness after mean 11.3-year follow-up (mori2025genomewideassociationand pages 1-2); with half-dose PDT treatment, approximately 95% achieve visual acuity of 20/30 or better (zhang2023centralserouschorioretinopathy pages 1-2)

Recurrence and Complications

  • Recurrence rates: 15–50% overall; untreated patients 51% vs. 25% in PDT-treated patients in acute CSC (kim2025treatmentofcentral pages 2-3, kim2025treatmentofcentral pages 8-9)
  • CNV develops in 2–15.6% of chronic cases (zhang2023centralserouschorioretinopathy pages 5-7, kim2025treatmentofcentral pages 3-5)
  • Progressive RPE atrophy, photoreceptor deterioration, and ganglion cell loss contribute to long-term morbidity (zhang2023centralserouschorioretinopathy pages 5-7)

Prognostic Factors

Poor prognostic indicators include persistent SRF >3–4 months, subfoveal choroidal thickness >500 µm, PED height >50 µm, age >40 years, bilateral involvement, and corticosteroid use (kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 2-4).

12. Treatment

The following table summarizes current and experimental treatment modalities for CSC:

Treatment Mechanism Indication/Subtype Efficacy (SRF resolution rate, VA outcome) Key Clinical Trials Level of Evidence/Recommendation
Half-dose verteporfin photodynamic therapy (PDT) Reduces choroidal hyperpermeability and induces choriocapillaris vascular remodeling, decreasing leakage and pachychoroid-driven fluid accumulation Best-supported treatment for chronic CSC; also considered in acute CSC when rapid recovery is needed, in recurrent disease, or single seeing eye Chronic CSC: ~95% achieve VA 20/30 or better in review-level summary; SRF resolution 91% at 19 months and 81% at 50 months; recurrence reduced to ~20% vs 53.8% with observation; faster SRF and retinal sensitivity recovery than no treatment (zhang2023centralserouschorioretinopathy pages 1-2, kim2025treatmentofcentral pages 8-9) PLACE trial; SPECTRA trial (zhang2023centralserouschorioretinopathy pages 19-20, kim2025treatmentofcentral pages 12-13) Highest current evidence; treatment of choice/mainstay for chronic CSC in recent expert reviews and consensus-style guidance (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 8-9, zhang2023centralserouschorioretinopathy pages 1-2)
Half-fluence PDT Same core PDT effect with reduced laser fluence to limit adverse effects while maintaining choroidal remodeling Alternative reduced-setting PDT for chronic CSC; sometimes used in acute CSC Effective and broadly comparable to half-dose PDT in review summaries; early treatment may speed fluid resolution and visual recovery, but half-dose has the strongest supporting data (zhang2023centralserouschorioretinopathy pages 14-15, kim2025treatmentofcentral pages 8-9) Comparative PDT studies referenced in reviews; PLACE-related comparative context (zhang2023centralserouschorioretinopathy pages 14-15, zhang2023centralserouschorioretinopathy pages 19-20) Strong evidence, but generally considered slightly less established than half-dose PDT as preferred regimen (kim2025treatmentofcentral pages 8-9, zhang2023centralserouschorioretinopathy pages 1-2)
Eplerenone / spironolactone Mineralocorticoid receptor antagonism targeting corticosteroid/mineralocorticoid pathway implicated in CSC Chronic CSC when PDT is unavailable/contraindicated; historically used off-label Evidence mixed to negative for routine use: VICI showed eplerenone failed primary BCVA outcome at 12 months in chronic CSC; some smaller studies suggested anatomical benefit, but overall efficacy remains controversial (kim2025treatmentofcentral pages 9-10, zhang2023centralserouschorioretinopathy pages 1-2) VICI trial; SPECTRA trial (direct comparison with half-dose PDT) (zhang2023centralserouschorioretinopathy pages 19-20, kim2025treatmentofcentral pages 12-13) Moderate/low certainty for routine care; not preferred over PDT in current reviews (kim2025treatmentofcentral pages 9-10, zhang2023centralserouschorioretinopathy pages 1-2)
Anti-VEGF intravitreal therapy (bevacizumab, ranibizumab, aflibercept) Suppresses VEGF-driven neovascular leakage CSC complicated by type 1 CNV / macular neovascularization; not standard for uncomplicated CSC Standard and effective for CSC with active CNV; meta-analysis did not confirm efficacy in acute CSC without CNV; aflibercept trial showed better BCVA gain than sham, and ranibizumab was inferior to low-fluence PDT anatomically in non-CNV settings (kim2025treatmentofcentral pages 9-9, zhang2023centralserouschorioretinopathy pages 14-15) MINERVA trial; aflibercept randomized study referenced in review (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 9-9) Strong recommendation only when CNV is present; not recommended as routine monotherapy for non-neovascular CSC (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 9-9)
Focal laser photocoagulation Seals focal extrafoveal leakage sites Acute or chronic CSC with extrafoveal focal leakage on FA/ICGA May accelerate fluid resolution; some long-term studies suggest fewer recurrences and better 5-year VA than observation, but does not address underlying choroidal disease and may not reduce recurrence in all studies (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 7-8) Older comparative laser vs observation studies summarized in reviews (kim2025treatmentofcentral pages 7-8) Reasonable for selected extrafoveal leakage; inferior to PDT for chronic subfoveal disease (kim2025treatmentofcentral pages 9-10, zhang2023centralserouschorioretinopathy pages 1-2)
Subthreshold micropulse laser (e.g., 577 nm HSML) Delivers sublethal retinal laser energy with minimal tissue damage, aiming to stimulate RPE pump function Chronic CSC, especially when PDT unavailable, leakage is juxtafoveal/extrafoveal, or extensive RPE damage limits other options Complete SRF resolution reported in 36-100% across studies; one review cites 41% in focal leakage and 21% in diffuse leakage chronic CSC; PLACE trial showed inferiority to half-dose PDT for chronic CSC (kim2025treatmentofcentral pages 7-8, kim2025treatmentofcentral pages 8-9, zhang2023centralserouschorioretinopathy pages 14-15) PLACE trial; multiple HSML studies summarized in reviews (zhang2023centralserouschorioretinopathy pages 14-15, kim2025treatmentofcentral pages 12-13) Moderate evidence; useful alternative but generally less effective than half-dose PDT for chronic CSC (zhang2023centralserouschorioretinopathy pages 14-15, kim2025treatmentofcentral pages 8-9)
Rifampicin Alters glucocorticoid metabolism, potentially reducing corticosteroid-mediated CSC activity Selected patients unsuitable for invasive treatment; off-label systemic therapy Limited evidence for anatomical/clinical improvement in some studies; safety limited by need for hepatotoxicity monitoring (zhang2023centralserouschorioretinopathy pages 14-15, zhang2023centralserouschorioretinopathy pages 19-20) Small non-pivotal studies referenced in reviews (zhang2023centralserouschorioretinopathy pages 14-15, kim2025treatmentofcentral pages 12-13) Low-quality evidence; experimental/off-label adjunct rather than standard care (zhang2023centralserouschorioretinopathy pages 14-15)
Mifepristone / finasteride Hormonal pathway modulation: glucocorticoid/progesterone receptor antagonism (mifepristone) or androgen pathway modulation (finasteride) Experimental/off-label use in CSC linked to endocrine/hormonal mechanisms Insufficient robust efficacy data in recent reviews; discussed as potential options rather than established therapies (kim2025treatmentofcentral pages 12-13) Small exploratory studies referenced in review literature (kim2025treatmentofcentral pages 12-13) Low-quality evidence; not standard recommendation (kim2025treatmentofcentral pages 12-13)
Melatonin Proposed neurohormonal/chronobiologic and antioxidant effects; possible modulation of stress-related pathways Experimental; acute CSC under investigation No established efficacy in retrieved review evidence; ongoing phase 2/3 trial identified (NCT06809751) (OpenTargets Search: central serous chorioretinopathy) NCT06809751 (not yet recruiting) (OpenTargets Search: central serous chorioretinopathy) Investigational; insufficient evidence for routine use (OpenTargets Search: central serous chorioretinopathy)
Observation / risk-factor modification Allows spontaneous resolution while removing triggers (especially corticosteroids and stress-related factors) First-line for many acute CSC cases without severe visual demands or chronicity Acute CSC: ~90-95% spontaneously resolve; however recurrence remains substantial, and untreated eyes show higher recurrence than PDT-treated eyes in comparative studies (zhang2023centralserouschorioretinopathy pages 10-12, kim2025treatmentofcentral pages 8-9) Observation comparator arms in PDT studies; natural history data summarized in reviews (kim2025treatmentofcentral pages 8-9, zhang2023centralserouschorioretinopathy pages 10-12) Appropriate initial strategy for typical acute CSC; not preferred for persistent/chronic disease (kim2025treatmentofcentral pages 9-10, zhang2023centralserouschorioretinopathy pages 10-12)

Table: This table summarizes current treatment options for central serous chorioretinopathy, including mechanisms, indications, comparative efficacy, and the strength of supporting evidence. It is useful for quickly distinguishing standard-of-care therapies such as half-dose PDT from conditional, off-label, or investigational options.

Key Treatment Details

Half-Dose Photodynamic Therapy (PDT): The mainstay of treatment for chronic CSC, with SRF resolution rates of 91% at 19 months and 81% at 50 months follow-up. PDT reduces recurrence risk to approximately 20% compared to 53.8% with observation alone over ≥3-year follow-up (kim2025treatmentofcentral pages 8-9). PDT works through choriocapillaris vascular remodeling and decreased choroidal hyperpermeability (zhang2023centralserouschorioretinopathy pages 1-2). MAXO term: MAXO:0000127 (phototherapy).

Mineralocorticoid Receptor Antagonists (Eplerenone/Spironolactone): The randomized VICI trial showed eplerenone failed to meet its primary endpoint of improving BCVA at 12 months in chronic CSC, making its routine use controversial (kim2025treatmentofcentral pages 9-10, zhang2023centralserouschorioretinopathy pages 1-2). MAXO term: MAXO:0000010 (pharmacotherapy).

Anti-VEGF Therapy: Standard treatment specifically for CSC complicated by active choroidal neovascularization (type 1 CNV), supported by the MINERVA trial. Not effective as monotherapy for uncomplicated CSC (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 9-9). MAXO term: MAXO:0001298 (intravitreal injection).

Subthreshold Micropulse Laser: Complete SRF resolution in 36–100% of chronic CSC patients across studies; the PLACE trial showed inferiority to half-dose PDT (kim2025treatmentofcentral pages 7-8, zhang2023centralserouschorioretinopathy pages 14-15).

Focal Laser Photocoagulation: Appropriate for extrafoveal leakage points identified on FA/ICGA (kim2025treatmentofcentral pages 9-10, kim2025treatmentofcentral pages 7-8). MAXO term: MAXO:0010022 (laser photocoagulation).

Active Clinical Trials

Current recruiting trials include studies evaluating gut microbiota associations (NCT06527326), micropulse laser treatment (NCT06346405), choroidal blood flow assessment (NCT05589974), and subthreshold nanosecond laser (NCT05570591). A phase 2/3 trial evaluating oral melatonin for acute CSC (NCT06809751) is not yet recruiting.

13. Prevention

Primary Prevention

  • Corticosteroid avoidance/minimization: The most important modifiable risk factor. Discontinuation of corticosteroids (oral, inhaled, nasal, topical) is recommended when possible (kim2025treatmentofcentral pages 2-3, zhang2023centralserouschorioretinopathy pages 2-4)
  • Stress management: Given the strong association with psychological stress and Type A personality, stress reduction strategies may reduce onset and recurrence risk (zhang2023centralserouschorioretinopathy pages 2-4)
  • Sleep disorder management: Treatment of obstructive sleep apnea (5× increased risk) may be preventive (kim2025treatmentofcentral pages 2-3)

Secondary Prevention

  • Risk factor modification: Corticosteroid discontinuation and stress reduction can enhance vision recovery in acute CSC (zhang2023centralserouschorioretinopathy pages 10-12)
  • Early treatment: Early half-dose PDT for recurrent or non-resolving cases reduces recurrence from 24% to 4% (kim2025treatmentofcentral pages 8-9)

Tertiary Prevention

  • Monitoring for CNV: Regular OCT/OCTA follow-up for chronic CSC patients to detect type 1 CNV early (kim2025treatmentofcentral pages 3-5)
  • Appropriate treatment escalation: Transition from observation to PDT treatment when SRF persists >3–4 months (zhang2023centralserouschorioretinopathy pages 10-12)

Genetic Counseling

CSC is a complex, multifactorial disease without a defined Mendelian inheritance pattern. While genetic risk factors have been identified (particularly CFH, PTPRB), genetic counseling is not routinely recommended as no single gene drives disease (mori2025genomewideassociationand pages 2-3, ramo2025raregeneticvariation pages 1-2).

14. Other Species / Natural Disease

Animal Models

Several animal models have been developed to study CSC pathogenesis:

  • Aldosterone-induced rat model: Melatonin has been shown to prevent experimental CSC in rats treated with aldosterone, supporting the mineralocorticoid receptor pathway in pathogenesis (Yu et al. 2022, doi:10.1111/jpi.12802)
  • Choroidal congestion mouse model: Matsumoto et al. (2021) developed a choroidal congestion model as a potential pachychoroid model (doi:10.1371/journal.pone.0246115)
  • Adrenaline-induced chinchilla rabbit model: Intravenous adrenaline injection produces temporal topographic changes mimicking CSC features (Yan et al. 2023, doi:10.2147/dddt.s381957)
  • Adenosine A2A receptor antagonist model: KW6002 has been shown to mitigate aldosterone-induced CSC in mice (Liu et al. 2026, doi:10.1016/j.neuropharm.2026.111036)

These models recapitulate aspects of choroidal thickening, subretinal fluid accumulation, and RPE dysfunction but do not fully reproduce the complex multifactorial nature of human CSC.

15. Model Organisms

Available Models

  • Rat (Rattus norvegicus, NCBI Taxon:10116): Aldosterone-induced model showing subretinal fluid and RPE changes
  • Mouse (Mus musculus, NCBI Taxon:10090): Choroidal congestion model; adenosine receptor-related models
  • Rabbit (Oryctolagus cuniculus, NCBI Taxon:9986): Adrenaline-induced model

Model Limitations

Current models primarily address individual pathogenic mechanisms (hormonal, vascular congestion) rather than the full spectrum of genetic susceptibility, complement pathway involvement, and chronic disease features seen in human CSC. No transgenic or knockout models specifically targeting CSC susceptibility genes (CFH, PTPRB, TNFRSF10A) have been reported in the retrieved literature.

Summary of Key Ontology Annotations

Disease: MONDO:0007381; EFO_0009784; ICD-10: H35.71 Phenotypes (HPO): HP:0000572 (visual loss), HP:0007401 (macular atrophy), HP:0011506 (choroidal neovascularization), HP:0000580 (pigmentary retinopathy) Anatomical structures (UBERON): UBERON:0000966 (retina), UBERON:0001776 (choroid), UBERON:0000053 (macula lutea) Cell types (CL): CL:0002586 (retinal pigment epithelial cell), CL:0000210 (photoreceptor cell) Biological processes (GO): GO:0006956 (complement activation), GO:0006979 (response to oxidative stress), GO:0001974 (blood vessel remodeling), GO:0045766 (positive regulation of angiogenesis) Treatments (MAXO): MAXO:0000127 (phototherapy), MAXO:0000010 (pharmacotherapy), MAXO:0001298 (intravitreal injection), MAXO:0010022 (laser photocoagulation) Chemical entities (CHEBI): CHEBI:50858 (corticosteroid), CHEBI:6781 (mineralocorticoid), CHEBI:145022 (eplerenone), CHEBI:50267 (verteporfin)

This report integrates evidence from 10 primary literature sources, 13 clinical trials, and OpenTargets disease-target association data. Disease information is derived from aggregated disease-level resources including comprehensive reviews, GWAS meta-analyses, and clinical trial data rather than individual patient electronic health records.

References

  1. (zhang2023centralserouschorioretinopathy pages 1-2): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  2. (kim2025treatmentofcentral pages 2-3): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  3. (OpenTargets Search: central serous chorioretinopathy): Open Targets Query (central serous chorioretinopathy, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  4. (zhang2023centralserouschorioretinopathy pages 2-4): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  5. (ramo2024raregeneticvariation pages 30-33): Joel T Rämö, Bryan Gorman, Lu-Chen Weng, Sean J Jurgens, Panisa Singhanetr, Marisa G Tieger, Elon HC van Dijk, Christopher W Halladay, Xin Wang, Joost Brinks, Seung Hoan Choi, Yuyang Luo, Saiju Pyarajan, Cari L Nealon, Michael B Gorin, Wen-Chih Wu, Lucia Sobrin, Kai Kaarniranta, Suzanne Yzer, Aarno Palotie, Neal S Peachey, Joni A Turunen, Camiel JF Boon, Patrick T Ellinor, Sudha K Iyengar, Mark J Daly, and Elizabeth J Rossin. Rare genetic variation in ve-ptp is associated with central serous chorioretinopathy, venous dysfunction and glaucoma. medRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.08.24307013, doi:10.1101/2024.05.08.24307013. This article has 1 citations.

  6. (mori2025genomewideassociationand pages 2-3): Yuki Mori, E. H. V. van Dijk, M. Miyake, Yoshikatsu Hosoda, A. D. den Hollander, S. Yzer, Akiko Miki, Li Jia Chen, Jeeyun Ahn, Ayako Takahashi, Kazuya Morino, Shin-Ya Nakao, C. Hoyng, D. S. Ng, Ling-Ping Cen, Haoyu Chen, T. Ng, C. P. Pang, Kwangsic Joo, Takehiro Sato, Yasuhiko Sakata, Atsushi Tajima, Y. Tabara, Yasuharu Takeo Akihiro Shinji Fumihiko Tabara Nakayama Sekine Kosugi Matsuda, Takeo Nakayama, Akihiro Sekine, S. Kosugi, Fumihiko Matsuda, Kyu Hyung Park, K. Yamashiro, Shigeru Honda, Masao Nagasaki, C. Boon, and A. Tsujikawa. Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy. Scientific Reports, Mar 2025. URL: https://doi.org/10.1038/s41598-025-92210-6, doi:10.1038/s41598-025-92210-6. This article has 6 citations and is from a peer-reviewed journal.

  7. (ramo2025raregeneticvariation pages 1-2): Joel T. Rämö, Bryan R. Gorman, Lu-Chen Weng, Sean J. Jurgens, Panisa Singhanetr, Marisa G. Tieger, Elon HC van Dijk, Christopher W. Halladay, Xin Wang, Blake M. Hauser, Soo Hyun Kim, Joost Brinks, Seung Hoan Choi, Yuyang Luo, Saiju Pyarajan, Cari L. Nealon, Michael B. Gorin, Wen-Chih Wu, Scott A. Anthony, David P. Roncone, Lucia Sobrin, Kai Kaarniranta, Suzanne Yzer, Aarno Palotie, Neal S. Peachey, Joni A. Turunen, Camiel JF Boon, Patrick T. Ellinor, Sudha K. Iyengar, Mark J. Daly, and Elizabeth J. Rossin. Rare genetic variation in ptprb is associated with central serous chorioretinopathy, varicose veins and glaucoma. Nature Communications, May 2025. URL: https://doi.org/10.1038/s41467-025-58686-6, doi:10.1038/s41467-025-58686-6. This article has 13 citations and is from a highest quality peer-reviewed journal.

  8. (mori2025genomewideassociationand pages 11-11): Yuki Mori, E. H. V. van Dijk, M. Miyake, Yoshikatsu Hosoda, A. D. den Hollander, S. Yzer, Akiko Miki, Li Jia Chen, Jeeyun Ahn, Ayako Takahashi, Kazuya Morino, Shin-Ya Nakao, C. Hoyng, D. S. Ng, Ling-Ping Cen, Haoyu Chen, T. Ng, C. P. Pang, Kwangsic Joo, Takehiro Sato, Yasuhiko Sakata, Atsushi Tajima, Y. Tabara, Yasuharu Takeo Akihiro Shinji Fumihiko Tabara Nakayama Sekine Kosugi Matsuda, Takeo Nakayama, Akihiro Sekine, S. Kosugi, Fumihiko Matsuda, Kyu Hyung Park, K. Yamashiro, Shigeru Honda, Masao Nagasaki, C. Boon, and A. Tsujikawa. Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy. Scientific Reports, Mar 2025. URL: https://doi.org/10.1038/s41598-025-92210-6, doi:10.1038/s41598-025-92210-6. This article has 6 citations and is from a peer-reviewed journal.

  9. (ramo2024raregeneticvariation pages 1-4): Joel T Rämö, Bryan Gorman, Lu-Chen Weng, Sean J Jurgens, Panisa Singhanetr, Marisa G Tieger, Elon HC van Dijk, Christopher W Halladay, Xin Wang, Joost Brinks, Seung Hoan Choi, Yuyang Luo, Saiju Pyarajan, Cari L Nealon, Michael B Gorin, Wen-Chih Wu, Lucia Sobrin, Kai Kaarniranta, Suzanne Yzer, Aarno Palotie, Neal S Peachey, Joni A Turunen, Camiel JF Boon, Patrick T Ellinor, Sudha K Iyengar, Mark J Daly, and Elizabeth J Rossin. Rare genetic variation in ve-ptp is associated with central serous chorioretinopathy, venous dysfunction and glaucoma. medRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.08.24307013, doi:10.1101/2024.05.08.24307013. This article has 1 citations.

  10. (matet2020lipocalin2as pages 6-6): A. Matet, T. Jaworski, E. Bousquet, J. Canonica, C. Gobeaux, A. Daruich, Min Zhao, M. Zola, Magda A. Meester-Smoor, D. Mohabati, F. Jaisser, S. Yzer, and F. Behar-Cohen. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, Nov 2020. URL: https://doi.org/10.1038/s41598-020-77202-y, doi:10.1038/s41598-020-77202-y. This article has 26 citations and is from a peer-reviewed journal.

  11. (zhang2023centralserouschorioretinopathy pages 4-5): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  12. (mori2025genomewideassociationand pages 1-2): Yuki Mori, E. H. V. van Dijk, M. Miyake, Yoshikatsu Hosoda, A. D. den Hollander, S. Yzer, Akiko Miki, Li Jia Chen, Jeeyun Ahn, Ayako Takahashi, Kazuya Morino, Shin-Ya Nakao, C. Hoyng, D. S. Ng, Ling-Ping Cen, Haoyu Chen, T. Ng, C. P. Pang, Kwangsic Joo, Takehiro Sato, Yasuhiko Sakata, Atsushi Tajima, Y. Tabara, Yasuharu Takeo Akihiro Shinji Fumihiko Tabara Nakayama Sekine Kosugi Matsuda, Takeo Nakayama, Akihiro Sekine, S. Kosugi, Fumihiko Matsuda, Kyu Hyung Park, K. Yamashiro, Shigeru Honda, Masao Nagasaki, C. Boon, and A. Tsujikawa. Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy. Scientific Reports, Mar 2025. URL: https://doi.org/10.1038/s41598-025-92210-6, doi:10.1038/s41598-025-92210-6. This article has 6 citations and is from a peer-reviewed journal.

  13. (zhang2023centralserouschorioretinopathy pages 5-7): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  14. (mori2025genomewideassociationand pages 10-11): Yuki Mori, E. H. V. van Dijk, M. Miyake, Yoshikatsu Hosoda, A. D. den Hollander, S. Yzer, Akiko Miki, Li Jia Chen, Jeeyun Ahn, Ayako Takahashi, Kazuya Morino, Shin-Ya Nakao, C. Hoyng, D. S. Ng, Ling-Ping Cen, Haoyu Chen, T. Ng, C. P. Pang, Kwangsic Joo, Takehiro Sato, Yasuhiko Sakata, Atsushi Tajima, Y. Tabara, Yasuharu Takeo Akihiro Shinji Fumihiko Tabara Nakayama Sekine Kosugi Matsuda, Takeo Nakayama, Akihiro Sekine, S. Kosugi, Fumihiko Matsuda, Kyu Hyung Park, K. Yamashiro, Shigeru Honda, Masao Nagasaki, C. Boon, and A. Tsujikawa. Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy. Scientific Reports, Mar 2025. URL: https://doi.org/10.1038/s41598-025-92210-6, doi:10.1038/s41598-025-92210-6. This article has 6 citations and is from a peer-reviewed journal.

  15. (chen2026thecfh–cfhr5locus pages 10-10): Zhen Ji Chen, Jun Yu, Mary Ho, Danny S.C. Ng, Marten E. Brelen, Alvin L. Young, Jason C.S. Yam, Clement C. Tham, Chi Pui Pang, and Li Jia Chen. The cfh–cfhr5 locus in wet age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy. Ophthalmology Science, 6(2):101043, Feb 2026. URL: https://doi.org/10.1016/j.xops.2025.101043, doi:10.1016/j.xops.2025.101043. This article has 1 citations.

  16. (chen2026thecfh–cfhr5locus pages 8-9): Zhen Ji Chen, Jun Yu, Mary Ho, Danny S.C. Ng, Marten E. Brelen, Alvin L. Young, Jason C.S. Yam, Clement C. Tham, Chi Pui Pang, and Li Jia Chen. The cfh–cfhr5 locus in wet age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy. Ophthalmology Science, 6(2):101043, Feb 2026. URL: https://doi.org/10.1016/j.xops.2025.101043, doi:10.1016/j.xops.2025.101043. This article has 1 citations.

  17. (matet2020lipocalin2as pages 5-6): A. Matet, T. Jaworski, E. Bousquet, J. Canonica, C. Gobeaux, A. Daruich, Min Zhao, M. Zola, Magda A. Meester-Smoor, D. Mohabati, F. Jaisser, S. Yzer, and F. Behar-Cohen. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, Nov 2020. URL: https://doi.org/10.1038/s41598-020-77202-y, doi:10.1038/s41598-020-77202-y. This article has 26 citations and is from a peer-reviewed journal.

  18. (matet2020lipocalin2as pages 1-2): A. Matet, T. Jaworski, E. Bousquet, J. Canonica, C. Gobeaux, A. Daruich, Min Zhao, M. Zola, Magda A. Meester-Smoor, D. Mohabati, F. Jaisser, S. Yzer, and F. Behar-Cohen. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, Nov 2020. URL: https://doi.org/10.1038/s41598-020-77202-y, doi:10.1038/s41598-020-77202-y. This article has 26 citations and is from a peer-reviewed journal.

  19. (matet2020lipocalin2as pages 2-3): A. Matet, T. Jaworski, E. Bousquet, J. Canonica, C. Gobeaux, A. Daruich, Min Zhao, M. Zola, Magda A. Meester-Smoor, D. Mohabati, F. Jaisser, S. Yzer, and F. Behar-Cohen. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, Nov 2020. URL: https://doi.org/10.1038/s41598-020-77202-y, doi:10.1038/s41598-020-77202-y. This article has 26 citations and is from a peer-reviewed journal.

  20. (matet2020lipocalin2as pages 3-5): A. Matet, T. Jaworski, E. Bousquet, J. Canonica, C. Gobeaux, A. Daruich, Min Zhao, M. Zola, Magda A. Meester-Smoor, D. Mohabati, F. Jaisser, S. Yzer, and F. Behar-Cohen. Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Scientific Reports, Nov 2020. URL: https://doi.org/10.1038/s41598-020-77202-y, doi:10.1038/s41598-020-77202-y. This article has 26 citations and is from a peer-reviewed journal.

  21. (zhang2023centralserouschorioretinopathy pages 7-10): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  22. (kim2025treatmentofcentral pages 3-5): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  23. (zhang2023centralserouschorioretinopathy pages 10-12): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  24. (kim2025treatmentofcentral pages 11-11): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  25. (shojaeinia2025acomprehensiveoverview pages 1-2): Mohammad Shojaeinia, Azamossadat Hosseini, Mostafa Naderi, Bardia D Baloutch, Mohammad Shokoohi Yekta, Leila Akbarpour, and Hamid Moghaddasi. A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis. BMC Ophthalmology, Oct 2025. URL: https://doi.org/10.1186/s12886-025-04372-6, doi:10.1186/s12886-025-04372-6. This article has 5 citations and is from a peer-reviewed journal.

  26. (shojaeinia2025acomprehensiveoverview pages 14-16): Mohammad Shojaeinia, Azamossadat Hosseini, Mostafa Naderi, Bardia D Baloutch, Mohammad Shokoohi Yekta, Leila Akbarpour, and Hamid Moghaddasi. A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis. BMC Ophthalmology, Oct 2025. URL: https://doi.org/10.1186/s12886-025-04372-6, doi:10.1186/s12886-025-04372-6. This article has 5 citations and is from a peer-reviewed journal.

  27. (shojaeinia2025acomprehensiveoverview pages 13-14): Mohammad Shojaeinia, Azamossadat Hosseini, Mostafa Naderi, Bardia D Baloutch, Mohammad Shokoohi Yekta, Leila Akbarpour, and Hamid Moghaddasi. A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis. BMC Ophthalmology, Oct 2025. URL: https://doi.org/10.1186/s12886-025-04372-6, doi:10.1186/s12886-025-04372-6. This article has 5 citations and is from a peer-reviewed journal.

  28. (shojaeinia2025acomprehensiveoverview pages 8-9): Mohammad Shojaeinia, Azamossadat Hosseini, Mostafa Naderi, Bardia D Baloutch, Mohammad Shokoohi Yekta, Leila Akbarpour, and Hamid Moghaddasi. A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis. BMC Ophthalmology, Oct 2025. URL: https://doi.org/10.1186/s12886-025-04372-6, doi:10.1186/s12886-025-04372-6. This article has 5 citations and is from a peer-reviewed journal.

  29. (kim2025treatmentofcentral pages 8-9): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  30. (zhang2023centralserouschorioretinopathy pages 19-20): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  31. (kim2025treatmentofcentral pages 12-13): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  32. (kim2025treatmentofcentral pages 9-10): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  33. (zhang2023centralserouschorioretinopathy pages 14-15): Xinyuan Zhang, Connie Zhi Fong Lim, Jay Chhablani, and Yew Meng Wong. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vision, Jul 2023. URL: https://doi.org/10.1186/s40662-023-00349-y, doi:10.1186/s40662-023-00349-y. This article has 84 citations and is from a peer-reviewed journal.

  34. (kim2025treatmentofcentral pages 9-9): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

  35. (kim2025treatmentofcentral pages 7-8): Yoon Jeon Kim, Sobha Sivaprasad, Tariq Aslam, Polona Jaki Mekjavić, Vilma Jūratė Balčiūnienė, Linda Visser, Antonia M. Joussen, Young Hee Yoon, Timothy Y. Y. Lai, and Annabelle A. Okada. Treatment of central serous chorioretinopathy: new options for an old disease. Eye, 39:2375-2388, Jul 2025. URL: https://doi.org/10.1038/s41433-025-03894-z, doi:10.1038/s41433-025-03894-z. This article has 9 citations and is from a peer-reviewed journal.

Artifacts